


### FINAL REPORT

March 2024

# Overview of Current Performance Measures Included in Selected Medicare Payment Programs





## **Table of Contents**

| Executive Summary  | 2    |
|--|------|
| ntroduction  | 7    |
| Methods  | 10   |
| Results  | 11   |
| Analysis 1: Performance Measure-Level Analysis Using Data from the CMS Measures Inventory Tool (CMIT)  |      |
| Analysis 2: How Performance Measures are Tied to Payment   | . 28 |
| Analysis 3: Gaps in Current Performance Measures   | . 34 |
| Appendix A. Methodology  | 35   |
| Appendix B. Detailed Performance Measure-Level Information Based on an Analysis of Data from the CMIT for 24 Selected Medicare Programs/Models | 37   |
| Appendix C. Detailed Information on Current Performance Measures for 14 Selected CMMI Models   | 41   |
| Appendix D. Detailed Information on Current Performance Measures for Four Selected Medicare Payment Programs                                   | 82   |
| Appendix E. Programs and Models Included in the CMIT Table, Detailed Tables, or Both   | 94   |



## List of Exhibits

| Exhibit 1.  | Programs and Models Included in the Three Types of Analyses   | 7  |
|-------------|---|----|
| Exhibit 2.  | Number of Current Performance Measures in the CMIT for Selected Programs/Models   | 12 |
| Exhibit 3.  | Number of Current Performance Measures by Program/Model   | 13 |
| Exhibit 4.  | Two Examples of Measures Where Programs/Models Apply Different Criteria to the Same Measure   | 14 |
| Exhibit 5.  | Top Eight Performance Measures by Number of Programs/Models   | 14 |
| Exhibit 6.  | Number of Performance Measures Used for Only One Program/Model  | 16 |
| Exhibit 7.  | Performance Measure Groupings for Measures Focused on Similar Aspects of Care Across the 24 Programs/Models                                   | 17 |
| Exhibit 8.  | CMS Definitions of the Seven Performance Measure Types  | 18 |
| Exhibit 9.  | Distribution of Performance Measures by Measure Type for the 24 Programs/Models   | 19 |
| Exhibit 10. | Distribution of Performance Measures by Program/Model and Measure Type  | 20 |
| Exhibit 11. | Distribution of Performance Measures by Data Sources for the 24 Programs/Models   | 23 |
| Exhibit 12. | Distribution of Performance Measures by Reporting Level for the 24 Programs/Models  | 24 |
| Exhibit 13. | Distribution of Performance Measures by Endorsement Status for 24 Programs/Models.  | 25 |
| Exhibit 14. | Distribution of the 24 Programs/Models by Relationship to Provider Payment  | 26 |
| Exhibit 15. | Program/Model Type Definitions  | 27 |
| Exhibit 16. | Distribution of Performance Measures Based on How the 24 Selected Programs/Models are Linked with Payment                                     |    |
| Exhibit 17. | Performance-Based Payment Example: BPCI-A Model   | 30 |
| Exhibit 18. | Payment Information for 18 Programs/Models  | 30 |
| Exhibit B1. | Detailed Information for Each Performance Measure in the 2023 Performance Measure Data for 24 CMS Models and Programs Supplemental Excel File | 39 |
| Exhibit C1. | Program Description, Technical Issues, and Gaps Related to Current Performance Measures   | 41 |
| Exhibit C2. | Lessons Learned   | 74 |
| Exhibit D1. | Program Description, Technical Issues, and Gaps Related to Current Performance Measures   | 82 |
| Exhibit D2. | Lessons Learned   | 92 |



## Overview of Current Performance Measures Included in Selected Medicare Payment Programs

The Physician-Focused Payment Model Technical Advisory Committee (PTAC) conducted a theme-based discussion on developing and implementing performance measures for population-based total cost of care models during the Committee's March 25-26, 2024, public meeting. Prior to the March 2024 public meeting, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) requested an analysis on the "Overview of Current Performance Measures Included in Selected Medicare Payment Programs" to provide an overview of the number and characteristics of the performance measures that are currently being used in **31** selected Centers for Medicare & Medicaid Services (CMS) Medicare payment programs and Center for Medicare and Medicaid Innovation (CMMI) models This analysis was prepared under Contract Number HHSP233201500048I75P00123F37023 between the Department of Health and Human Services' Office of Health Policy of the ASPE and NORC at the University of Chicago. The opinions and views expressed in this analysis are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor, or any other funding organizations. This analysis was completed in March 2024.



## **Executive Summary**

#### Introduction

This report was prepared at the request of the Office of the Assistant Secretary for Planning and Evaluation (ASPE) as background information to assist the Physician-Focused Payment Model Technical Advisory Committee (PTAC) in preparing for a theme-based discussion on developing and implementing performance measures for population-based total cost of care (PB-TCOC) models.

This report provides an overview of the number and characteristics of the performance measures that are currently being used in **31** selected Centers for Medicare & Medicaid Services (CMS) Medicare payment programs and Center for Medicare and Medicaid Innovation (CMMI) models.

#### Methods

#### **Analyses and Data Sources**

Three types of analyses were conducted using the following data sources: 1) a high-level analysis of performance measure data for 24 selected programs/models using the CMS Measures Inventory Tool (CMIT); 2) information on how performance is linked with payment using information from CMS program and CMMI Innovation Models websites for 18 selected programs/models; and 3) an assessment of potential gaps in current performance measures using publicly available evaluation reports for 18 selected programs/models.

#### **Program Selection**

A total of 31 Medicare models and programs were selected for these analyses, including: 17 Medicare payment programs (nine CMS value-based care programs and eight CMS pay-for-reporting programs), and 14 CMMI models. The CMS programs (17) were selected to ensure the inclusion of a variety of Medicare performance reporting programs (e.g., pay-for-performance, pay-for-reporting, quality reporting, and other approaches). The CMMI models (14) were selected based on the following criteria: 1) the model must have been active in the last five years; 2) the model must include at least one quality measure and at least one utilization or spending measure in implementation and/or monitoring; and 3) the model must be or have been operational in more than one state.



#### Results

#### **Analysis 1: Performance Measure-Level Analysis Using CMIT Data**

#### Total Current Performance Measures

There are 618 active, in-development, pending, or suspended performance measures (hereinafter referred to as "current performance measures" or "performance measures") in the CMIT for the 24 selected programs and models included in this analysis. The Merit-based Incentive Payment System (MIPS) Program included the most performance measures among the 24 programs/models with 309 performance measures (50% of the 618 measures).<sup>1</sup>

The number of measures included in the other 23 programs/models ranged from 3-33. The Medicare Advantage (MA) Star Ratings Program included the second most performance measures with 33 performance measures (5% of the 618 measures).

#### Distinct Performance Measures

Of the 618 current performance measures used by the 24 selected Medicare programs/ models, there are 455 "distinct" or unduplicated measures.<sup>2</sup> This includes 375 measures that are only used by one program/model (61% of the 618 current performance measures). The most common current performance measure is COVID-19 Vaccination Coverage Among Healthcare Personnel (measure ID: 180) which is used by eight of the 24 programs/models in this analysis (33%).

Additionally, there are 163 measures (26%) that are used by more than one program. These 163 measures may use different numerators, denominators, or denominator exclusions.

#### Distinct Measures Focused on Similar Aspects of Care

In addition to measures that are repeated across programs, some programs/models include performance measures that are distinct, but similar to other measures. The top three performance measure groupings for measures focused on similar aspects of care across the 455 distinct measures for the 24 programs/models are 1) screening measures (31 measures, 6.8% of the distinct measures); 2) therapy-related measures for certain chronic conditions (29 measures, 6.4%); and 3) medication-related measures (21 measures; 4.6%).

Final | March 2024

<sup>&</sup>lt;sup>1</sup> Participants in MIPS choose at least six quality measures (one must be an outcome measure) from the full list of measures, and CMS calculates and scores each participant on four administrative claims measures. Participants are not scored on all measures.

<sup>&</sup>lt;sup>2</sup> The number of distinct measures represents the number of current performance measures with distinct names (i.e., if each measure name is counted one time).



#### Types of Performance Measures

The CMIT includes seven types of performance measures: process, outcome, intermediate outcome, patient-reported, cost/resource use, structure, and composite measures. Of the 618 performance measures included across the 24 programs/models, more than half of the performance measures (323 measures or 52%) were process measures. Outcome measures were the second most common measure type (26%, n=163).

#### Sources of Performance Measures

The CMIT includes eight performance measure data sources: registries, claims data, electronic clinical data (non-EHR), electronic health records (EHRs), paper medical records, standardized patient assessments, administrative data (non-claims), and patient-reported data and surveys. Of the 618 performance measures included among the 24 programs/models, data sources were spread across the eight different sources. Registry data are the most common performance measure data source used among the 24 models/programs accounting for 24% of measures (n=229).

About half (54%) of the 618 existing performance measures are from electronic sources, including claims data (21%, n=202), EHR data (16%, n=150), and non-EHR electronic clinical data (17%, n=161), Meanwhile, 246 of the 618 measures (40%) use multiple data sources for a given performance measure.

#### Measure Reporting Level

Of the 618 performance measures included among the 24 programs/models, 31% (n=191) of the measures are reported at the facility, hospital, or agency level; 28% (n=176) are reported at the clinician group practice level. About 28% (n=173) of performance measures do not specify level of reporting.

#### Performance Measure Endorsement Status

The CMIT includes information on whether the performance measure is endorsed by the CMS Consensus-Based Entity (CBE)<sup>3</sup>. About 34% (n=209) of performance measures are endorsed, 59% (n=366) of measures are not endorsed, and endorsement has been removed for 7% (n=42). Twentythree of the programs/models have at least one endorsed measure; the MA Star Ratings is the only program without any endorsed measures. For two programs – Hospital Acquired Condition (HAC) Reduction Program and Hospital Readmission Reduction Program (HRRP) – all of the active performance measures are endorsed (six measures each).

<sup>&</sup>lt;sup>3</sup> The CMS consensus-based entity provides endorsement and maintenance of healthcare performance measures that are used throughout CMS programs, recommendations during CMS' pre-rulemaking consideration of measures, and input on integrated national strategies for performance measurement across payers.



#### Whether Performance Measures are Tied to Payment

The 24 selected programs/models were categorized as pay-for-performance, pay-for-reporting, or not related to payment based on information from the CMS program and CMMI Innovation Models websites. Fifteen of the 24 programs/models (63%) were characterized as pay-for-performance, defined as programs/models that are focused on providing payment to providers based on outcomes of patients; providing better outcomes results in higher payments. Eight of the 24 programs/models (33%) were characterized as pay-for-reporting, defined as programs/models that are required to report quality measure data to CMS and result in a decrease to Medicare payments for nonperformance. One of the selected programs (4%), the Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (CHQR), does not currently tie performance measures to payment.

We also examined the distribution of the 618 performance measures based on how the 24 programs/models are linked with payment. Seventy-seven percent (n=476) of the measures correspond with the 15 pay-for-performance programs/models (50% [n=309] are MIPS performance measures, while the remaining 27% [n=167] correspond to the other 14 pay-for-performance programs/models). Twenty percent (n=126) of the measures correspond with the eight pay-for-reporting programs, and three percent of the measures correspond with the one program (PPS-Exempt CHQR) that is not linked with payment.

#### **Analysis 2: How Performance Measures are Tied to Payment**

This second analysis focuses on 18 selected programs/models (14 CMMI models and four CMS value-based payment programs) where information on whether and how performance measures are tied to payment was obtained by reviewing CMS program and CMMI Innovation Models websites. All 18 of these models and programs adjust payment based on performance. Thirteen (72%) of the models and programs employ both upside and downside risk for participants. The Making Care Primary (MCP) Model, Independence-at-Home (IAH) Demonstration, Comprehensive Primary Care Plus (CPC+) Model, Oncology Care Model (OCM), and Medicare Advantage (MA) Star Ratings Program employ upside risk only.

A detailed review of the BPCI-A model was performed to provide an example of how performance measures are tied to payment. Participants in the BPCI-A model have the option of selecting either the Administrative Quality Measure (QM) set, or the Alternative QM set for a given clinical episode category. Reconciliation is based on comparing actual Medicare FFS expenditures for all items and services included in a clinical episode with the final total price for that episode. At reconciliation, CMS determines whether participants receive a payment or are required to pay a repayment amount.

Participants receive a Composite Quality Score (CQS) based on the applicable quality measures for the clinical episode. CMS uses the CQS to apply an adjustment amount of up to 10% for the total reconciliation amounts.



#### **Analysis 3: Potential Gaps in Current Performance Measures**

This third analysis also focuses on the 18 selected programs/models (14 CMMI models and four CMS value-based payment programs) that adjust payment based on performance. Information on potential gaps in current performance measures was obtained by reviewing publicly available evaluation reports. In the evaluations of the programs and models, various performance measure gaps have been identified. Concerns that have been identified range from the need to have increased financial incentives linked to performance measures to challenges related to the lack of specificity in certain measures. Additionally, few CMMI models incorporated guardrails to prevent unintended consequences, such as worsening disparities.



#### Introduction

This report was prepared at the request of the Office of the Assistant Secretary for Planning and Evaluation (ASPE) as background information to assist the Physician-Focused Payment Model Technical Advisory Committee (PTAC) in preparing for a theme-based discussion on developing and implementing performance measures for population-based total cost of care (PB-TCOC) models. Key findings from this report will be included in an environmental scan being prepared for this theme-based discussion.

This report provides an overview of the number and characteristics of performance measures currently used by **31** selected Centers for Medicare & Medicaid Services (CMS) Medicare payment programs (including 9 CMS value-based care programs and 8 CMS pay-for-reporting programs), and 14 Center for Medicare and Medicaid Innovation (CMMI) models based on the results of three types of analyses (**see Exhibit 1**).<sup>4</sup> Of the 31 selected programs/models, 24 are included in an analysis of data from the CMS Measures Inventory Tool (CMIT) and seven models are not part of the CMIT (details on program/model selection are provided below).

**Exhibit 1.** Programs and Models Included in the Three Types of Analyses

|  | Ту  | pe of Analysis Conduc                                       | ted  |
|--|---|---|--|
| Program / Model Name   | CMS Measures<br>Inventory Tool<br>(CMIT) Analysis | Information on How<br>Payment Is Linked<br>with Performance | Assessment of<br>Potential Gaps in<br>Current<br>Performance<br>Measures |
| TOTAL NUMBER OF SELECTED PROGRAMS / MODELS (31)                      | 24  | 18  | 18   |
| CMS PROGRAMS (17)  | 17  | 4   | 4  |
| Ambulatory Surgical Center (ASC)     Quality Reporting Program (QRP) | <b>~</b>  |   |  |
| End-Stage Renal Disease (ESRD)     Quality Incentive Program (QIP)   | <b>~</b>  |   |  |
| Home Health Quality Reporting (QR)                                   | <b>✓</b>  |   |  |

Final | March 2024

1

<sup>&</sup>lt;sup>4</sup> CMMI models are pilot programs that test new payment and service delivery methods in accordance with the requirements of section 1115A of the Social Security Act (https://www.cms.gov/priorities/innovation/models#views=models). CMMI models may go through several iterations and transitions to new or expanded models before formal implementation. CMS programs are already implemented programs that are part of the Medicare fee-for-service payment policy.



|   | Ту  | pe of Analysis Conduc                                       | ted  |
|---|---|---|--|
| Program / Model Name  | CMS Measures<br>Inventory Tool<br>(CMIT) Analysis | Information on How<br>Payment Is Linked<br>with Performance | Assessment of<br>Potential Gaps in<br>Current<br>Performance<br>Measures |
| Hospice Quality Reporting Program<br>(HQRP)   | <b>~</b>  |   |  |
| Hospital Acquired Condition (HAC)<br>Reduction Program  | <b>~</b>  |   |  |
| Hospital Outpatient Quality Reporting<br>(OQR) Program  | <b>~</b>  |   |  |
| Hospital Readmission Reduction<br>Program (HRRP)  | <b>~</b>  |   |  |
| Hospital Value-Based Purchasing<br>(VBP)  | <b>~</b>  | <b>~</b>  | <b>✓</b>   |
| Inpatient Psychiatric Facility (IPF)     Quality Reporting Program (QRP)  | <b>~</b>  |   |  |
| Inpatient Rehabilitation Facility (IRF)     Quality Reporting Program (QRP)   | <b>~</b>  |   |  |
| Long-Term Care Hospital (LTCH)     Quality Reporting Program (QRP)  | <b>~</b>  |   |  |
| Medicare Advantage (MA) Star<br>Ratings Program   | <b>~</b>  | <b>~</b>  | <b>~</b>   |
| Medicare Shared Savings Program<br>(MSSP)   | <b>~</b>  | <b>~</b>  | <b>✓</b>   |
| Merit-based Incentive Payment<br>System (MIPS) Program  | <b>~</b>  | <b>~</b>  | <b>✓</b>   |
| <ul> <li>Prospective Payment System (PPS)-<br/>Exempt Cancer Hospital Quality<br/>Reporting (CHQR) Program</li> </ul> | <b>~</b>  |   |  |
| Skilled Nursing Facility (SNF) Quality<br>Reporting Program (QRP)   | <b>~</b>  |   |  |
| Skilled Nursing Facility (SNF) Value-<br>Based Purchasing (VBP)   | <b>~</b>  |   |  |



|  | Ту  | pe of Analysis Conduc                                       | ted  |
|--|---|---|--|
| Program / Model Name   | CMS Measures<br>Inventory Tool<br>(CMIT) Analysis | Information on How<br>Payment Is Linked<br>with Performance | Assessment of<br>Potential Gaps in<br>Current<br>Performance<br>Measures |
| CMS CENTER FOR MEDICARE AND MEDICAID INNOVATION (CMMI) MODELS (14)                                       | 7   | 14  | 14   |
| Accountable Care Organization     (ACO) Realizing Equity, Access, and     Community Health (REACH) Model | <b>✓</b>  | ~   | <b>✓</b>   |
| Bundled Payment for Care<br>Improvement Advanced (BPCI-A)<br>Model                                       | <b>✓</b>  | ~   | <b>✓</b>   |
| Comprehensive ESRD Care (CEC)     Model  |   | <b>~</b>  | <b>~</b>   |
| Comprehensive Primary Care Plus<br>(CPC+) Model  |   | <b>~</b>  | <b>~</b>   |
| Enhancing Oncology Model (EOM)   |   | <b>~</b>  | <b>✓</b>   |
| ESRD Treatment Choices (ETC)     Model   |   | ~   | <b>~</b>   |
| Expanded Home Health Value-Based<br>Purchasing (HHVBP) Model   |   | <b>✓</b>  | <b>~</b>   |
| Home Health Value-Based<br>Purchasing (HHVBP) (original)   | <b>~</b>  | <b>✓</b>  | <b>~</b>   |
| Independence at Home (IAH)     Demonstration   | <b>~</b>  | <b>✓</b>  | <b>~</b>   |
| Kidney Care Choices (KCC) Model  | <b>~</b>  | <b>~</b>  | <b>~</b>   |
| Making Care Primary (MCP) Model  |   | <b>~</b>  | <b>✓</b>   |
| Next Generation ACO (NGACO)     Model  |   | <b>~</b>  | <b>~</b>   |
| Oncology Care Model (OCM)  | <b>~</b>  | <b>~</b>  | <b>~</b>   |
| Primary Care First (PCF) Model   | <b>~</b>  | <b>~</b>  | <b>✓</b>   |



#### Methods

#### **Analyses and Data Sources**

Three types of analyses were conducted using the following data sources:

- 1) Performance measure-level analysis for 24 selected programs/models using data from the CMS Measures Inventory Tool (CMIT). This analysis provides the following descriptive information about the performance measures included in these programs/models:
- Total performance measures
- Distinct performance measures
- · Measures focused on similar aspects of care
- · Types of performance measures
- · Sources of performance measures
- · Measure reporting level
- Performance measure endorsement status
- Whether performance measures are tied to payment<sup>5</sup>

The CMIT is a repository of performance measure information that includes 46 CMS value-based care programs, CMS pay-for-reporting programs, or CMMI models (as of October 2023 when CMIT data were pulled for this analysis). For each measure, the CMIT includes program/model name, measure name, measure definition, measure type, and measure source. Information from the CMIT was available for 24 of the 31 selected programs/models; seven models are not part of the CMIT. The supplemental Excel file (2023 Performance Measure Data for 24 CMS Models and Programs) contains three tabs. The first tab provides a description of the data included in the second tab of the supplemental Excel file. The second tab provides performance measure-level data obtained for the 24 programs/models pulled from the CMIT or from CMS/CMMI websites; the third tab provides a data dictionary that includes the column name, data sources, column name from the CMIT, definition, and whether the column is a CMIT required field. See Appendix B for additional information on the 2023 Performance Measure Data for 24 CMS Models and Programs supplemental Excel file.

Final | March 2024

<sup>&</sup>lt;sup>5</sup> The CMIT variable related to identifying if performance on a given measure is tied to payment for the applicable program/model is not a required field, and CMIT does not specify if performance is tied to payment for 60% (n=373) of the 618 performance measures identified in this analysis. This is a limitation of CMIT. Therefore the 24 selected programs/models were categorized as pay-for-performance, pay-for-reporting, or not related to payment based on information from the CMS website or the CMMI Innovation Models webpage.

<sup>&</sup>lt;sup>6</sup> Centers for Medicare and Medicaid Services Measures Inventory Tool, <a href="https://cmit.cms.gov/cmit/#/MeasureInventory">https://cmit.cms.gov/cmit/#/MeasureInventory</a>

<sup>&</sup>lt;sup>7</sup> The seven models not included in the CMIT are the Comprehensive End Stage Renal Disease (ESRD) Care (CEC) Model, Comprehensive Primary Care Plus (CPC+) Model, Enhancing Oncology Model (EOM), ESRD Treatment Choices (ETC) Model, Expanded Home Health Value-Based Purchasing (HHVBP) Model, Making Care Primary (MCP) Model, and the Next Generation Accountable Care Organization (NGACO) Model.



- 2) The second analysis focuses on assessing whether and how performance measures are linked with payment using information obtained from CMS program and CMMI Innovation Models websites. The report includes tables for the 14 selected CMMI models and four CMS value-based payment programs (out of the 17 programs referenced in Exhibit 1) that describe how performance measures are linked with payment.
- 3) The third analysis provides information on potential gaps in current performance measures using information obtained from publicly available evaluation reports for the 14 CMMI models and four programs.

Appendix C and Appendix D provide detailed payment information and potential gaps in current performance measures, as applicable, for the 18 programs/models (compiled in October 2023).

See Appendix E for a complete list of the 31 programs/models included in this analysis.

#### **Program Selection**

A total of 31 models and programs were selected for these analyses: 17 CMS Medicare value-based care programs (including 9 CMS value-based care programs and 8 CMS pay-for-reporting programs) and 14 CMMI models. The CMS programs (17) were selected to ensure a variety of Medicare performance reporting programs (e.g., pay-for-performance, pay-for-reporting, quality reporting, and other approaches). The CMMI models (14) were selected based on the following criteria: 1) the model must have been active in the last five years; 2) the model must include at least one quality measure and at least one utilization or spending measure in implementation and/or monitoring; and 3) the model must be or have been operational in more than one state. Information on the methods is also included in Appendix A.

#### Results

## Analysis 1: Performance Measure-Level Analysis Using Data from the CMS Measures Inventory Tool (CMIT)

#### **Total Current Performance Measures**

The CMIT includes information on performance measures for a total of 46 CMS programs and models. **Exhibit 2** summarizes the total number of performance measures included in CMIT, and the number of performance measures in CMIT for the 24 selected programs/models included in this analysis.



Exhibit 2. Number of Current Performance Measures in the CMIT for Selected Programs/Models

|   |                                  | Number of Performance Measures               |                                 |  |  |
|---|----------------------------------|--|---------------------------------|--|--|
| Description   | Number of<br>Programs/<br>Models | Total<br>Number<br>of<br>Current<br>Measures | Number of<br>Active<br>Measures | Number of Measures in<br>Development, Pending,<br>or Suspended |  |
| Selected Programs/Models<br>Included in This Analysis | 24                               | 618 <sup>1</sup>                             | 523                             | 89   |  |

Note: All data are as of October 2023, when CMIT data was pulled. Inactive measures, although available in the CMIT, were not included in the analysis, with the exception of the OCM.

The OCM has six measures; because the OCM is not an active model, the six measures are inactive. To include this model in this analysis, NORC included the six inactive measures associated with the OCM.

There are 618 active, in-development, pending, or suspended<sup>8</sup> performance measures<sup>9</sup> (hereinafter referred to as "current performance measures" or "performance measures") in the CMIT for the 24 selected programs and models included in this analysis. Of these 618 measures, 523 (84.6%) are actively being used in CMS programs, and 89 (14.4%) are in development, pending, or suspended. It is important to note that the 618 measures are not all unique as some measures are being used by multiple programs/models (see further discussion below).

**Exhibit 3** provides a breakdown of the number of current performance measures by program/model. The Merit-based Incentive Payment System (MIPS) Program includes the most performance measures among the 24 programs/models with 309 performance measures (50%) of the 618 measures. The number of measures included in the other 23 programs/models ranges from 3-33. The Medicare Advantage (MA) Star Ratings Program included the second most performance measures with 33 performance measures (5% of the 618 measures).

Of the seven CMMI models<sup>11</sup> included in the CMIT, the Bundled Payment for Care Improvement Advanced (BPCI-A) Model includes the most performance measures with 29 measures (5% of the 618 measures); the remaining six CMMI models use five to seven performance measures each.

Final | March 2024

Ω

<sup>&</sup>lt;sup>8</sup> Suspended measures may include measures that were temporarily suspended due to the Public Health Emergency (PHE). One example is the Skilled Nursing Facility (SNF) Value-Based Purchasing (VBP) measure, which uses the 30-day all-cause readmission measure; this measure is currently listed in the CMIT as suspended.

<sup>&</sup>lt;sup>9</sup> Inactive measures are not included with the exception of the Oncology Care Model (OCM); because this program is not active, all measures were also inactive. To include this model in this analysis, NORC included the six inactive measures tied to the OCM, which are a part of the 618 measures used in this analysis.


<sup>&</sup>lt;sup>10</sup> Participants in MIPS choose at least six quality measures (one must be an outcome measure) from the full list of measures, and CMS calculates and scores each participant on four administrative claims measures. Participants are not scored on all measures.

<sup>&</sup>lt;sup>11</sup> The seven models included are the Bundled Payment for Care Improvement Advanced (BPCI-A) Model; Accountable Care Organization (ACO) Realizing Equity, Access, and Community Health (REACH) Model; Home Health Value-Based Purchasing (HHVBP) Model; Independence at Home (IAH) Demonstration; Kidney Care Choices (KCC) Model; Oncology Care Model (OCM); and the Primary Care First (PCF) Model.



Exhibit 3. Number of Current Performance Measures by Program/Model





Note: Current performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.

#### **Distinct Performance Measures**

Most (75%) of the 618 current performance measures in the 24 programs/models included in this analysis are distinct or "unduplicated" measures (n=455). 12 This number includes active measures, as well as measures that are in development, pending, or suspended.

Further, 375 of the performance measures (61% of the 618 total current performance measures) are used for only one program or model.

<sup>&</sup>lt;sup>12</sup> The number of distinct measures represents the number of current performance measures with distinct names (i.e., if each measure name is counted one time).



Additionally, there are 163 measures (26% of the 618 total current performance measures) that are used by more than one program. These 163 measures may use different numerators, denominators, or denominator exclusions. Exhibit 5 provides two examples of measures that are used by more than one program but are defined in slightly different ways.

**Exhibit 4.** Two Examples of Measures Where Programs/Models Apply Different Criteria to the Same Measure

| Measure  | Program/Model  | Differences in Measure  |
|--|--|---|
| Colorectal Screening<br>(Measure ID: 139)          | Medicare Advantage (MA)<br>Star Ratings Program;<br>Medicare Shared Savings<br>Program (MSSP); Merit-<br>Based Incentive Payment<br>System (MIPS); Primary<br>Care First (PCF) Model | MIPS uses a denominator that includes patients 50-75 years of age while the three other programs/models use a denominator that includes patients 45-75 years of age.  |
| Controlling Blood<br>Pressure (Measure ID:<br>167) | MSSP; MIPS; PCF  | PCF differs in its denominator exclusion criteria from the other two programs: its denominator excludes pregnant women and does not exclude patients 81 years of age or older with an indication of frailty beyond those with advanced illness. |

**Exhibit 5** lists the eight<sup>13</sup> performance measures that are most often used across the 24 programs/models. The most common performance measure is COVID-19 Vaccination Coverage Among Healthcare Personnel (measure ID: 180) used by eight different programs (33%). The top eight measures listed in Exhibit 5 include four outcome measures, three process measures, and one cost/resource use measure.

**Exhibit 5.** Top Eight Performance Measures by Number of Programs/Models

| Measure<br>ID | Measure Name   | Measure Type | Number of<br>Programs/<br>Models | Included Programs <sup>14</sup>   |
|---------------|--|--------------|----------------------------------|---|
| 180           | COVID-19 Vaccination<br>Coverage Among Healthcare<br>Personnel | Process      | 8                                | LTCH QRP; PPS-Exempt<br>CHQR; ASCQR; ESRD QIP1;<br>Hospital OQR; IPF QR; IRF<br>QR; SNF QRP |

<sup>&</sup>lt;sup>13</sup> Top eight performance measures were chosen because it was a clean break from five to four programs; there were 13 performance measures with four programs each.

<sup>&</sup>lt;sup>14</sup> See Appendix E for the full names of each program/model.



| Measure<br>ID | Measure Name  | Measure Type         | Number of<br>Programs/<br>Models | Included Programs <sup>14</sup>   |
|---------------|---|----------------------|----------------------------------|---|
| 434           | Medicare Spending Per<br>Beneficiary (MSPB)   | Cost/Resource<br>Use | 6                                | Hospital VBP <sup>2</sup> ; IRF QR; MIPS;<br>LTCH QRP; SNF QRP; Home<br>Health QR     |
| 210           | Discharge to Community-Post<br>Acute Care (PAC)   | Outcome              | 6                                | Home Health VBP; Home<br>Health QR; IRF QR; LTCH<br>QR; SNF QRP; SNF VBP <sup>3</sup> |
| 462           | National Health Safety Network<br>(NHSN) Facility-Wide Inpatient<br>Hospital-Onset Clostridium<br>Difficile Infection (CDI) Outcome<br>Measure  | Outcome              | 5                                | HAC Reduction; Hospital<br>VBP <sup>4</sup> ; IRF QR; LTCH QRP;<br>PPS-Exempt CHQR    |
| 459           | NHSN Catheter-Associated<br>Urinary Tract Infection (UTI)<br>Outcome Measure  | Outcome              | 5                                | HAC Reduction; Hospital<br>VBP⁵; IRF QR; LTC QRP;<br>PPS-Exempt CHQR                  |
| 356           | Hospital-Wide All-Cause<br>Unplanned Readmission<br>Measure (HWR)   | Outcome              | 5                                | IAH Demonstration; ACO<br>REACH; BPCI-A; MSSP; MIPS                                   |
| 727           | Transfer of Health Information to<br>the Patient Post-Acute Care<br>(PAC) / Transition Record with<br>Specified Elements Received by<br>Discharged Patients (Discharges<br>from an Inpatient Facility to<br>Home/Self-care or Any Other<br>Site of Care) <sup>6</sup> | Process              | 5                                | Home Health QR; LTCH QR;<br>SNF QRP; IRF QR; IPF QR                                   |
| 728           | Transfer of Health Information to<br>the Provider PAC / Timely<br>Transmission of Transition<br>Record (Discharges from an<br>Inpatient Facility to Home/Self-<br>care or Any Other Site of Care) <sup>7</sup>  | Process              | 5                                | Home Health QR; LTCH QR;<br>SNF QRP; IRF QR; IPF QR                                   |

Note: All data are as of October 2023, when CMIT data was pulled. Unless otherwise indicated, measures included in this table are active within each program/model.

<sup>&</sup>lt;sup>1</sup>The COVID-19 Vaccination Coverage Among Healthcare Personnel Measure (measure ID 180) is a pending measure for the ESRD QIP.

<sup>&</sup>lt;sup>2</sup>The MSPB Measure (measure ID 434) is a suspended measure for the Hospital VBP Program.

<sup>&</sup>lt;sup>3</sup> The Discharge to Community-PAC Measure (measure ID 210) is a pending measure for the SNF VBP Program.

<sup>&</sup>lt;sup>4</sup> The NHSN Facility-Wide Inpatient Hospital-Onset CDI Outcome Measure (measure ID 462) is a suspended measure for the Hospital VBP Program.

<sup>&</sup>lt;sup>5</sup>The NHSN Catheter-Associated UTI Outcome Measure (measure ID 459) is a suspended measure for the Hospital VBP Program.

<sup>&</sup>lt;sup>6</sup> For measure ID 727, the IPF QR Program uses the measure name of Transition Record with Specified Elements Received by Discharged Patients (discharges from an inpatient facility to home/self-care or any other site of care); all other listed programs use the measure name of Transfer of Health Information to the Patient PAC.


<sup>&</sup>lt;sup>7</sup> For measure ID 728, the IPF QR Program uses the measure name of Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self-care or Any Other Site of Care); all other listed programs use the measure name of Transfer of Health Information to the Provider PAC.



Of the 618 total measures examined across the 24 programs/models, 375 measures (61%), involving 22 programs, are used by only one program/model. The Measure ID column from the CMIT was used to identify these measures. **Exhibit 6** provides the counts of performance measures used for only one program/model listed by program/model. Of the 375 performance measures used by only one program, 231 measures (62%) are used in only the MIPS Program. Other programs/models range from one to 27 measures that are specific only to that program or model. All except two programs/models (Medicare Shared Savings Program [MSSP] and Hospital Acquired Condition [HAC] Reduction Program) include measures exclusive to their programs/model.

Exhibit 6. Number of Performance Measures Used for Only One Program/Model

#### **Number of Performance Measures**



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.

Note: Two programs do not have measures exclusive to their programs (MSSP and HACRP).



#### Measures Focused on Similar Aspects of Care

In addition to measures that are repeated across programs, some programs include performance measures that are distinct, but similar to other measures. **Exhibit 7** provides a summary of distinct measures focused on similar aspects of care. These groupings do not capture all performance measures but offer a look at common measures used among these 24 programs/models.

**Exhibit 7.** Performance Measure Groupings for Measures Focused on Similar Aspects of Care Across the 24 Programs/Models

| Performance Measure Grouping                                      | Number of Performance<br>Measures | Percentage of Performance<br>Measures (Total n=455) |
|---|-----------------------------------|---|
| Screening Measures  | 31                                | 6.8%  |
| Therapy-Related Measures for Certain Chronic Conditions           | 29                                | 6.4%  |
| Medication-Related Measures                                       | 21                                | 4.6%  |
| Measures Related to Number/Rate of Admissions/Visits              | 20                                | 4.4%  |
| Follow-up-Related Measures after<br>Hospitalizations or ED Visits | 15                                | 3.3%  |
| Measures Related to Readmissions                                  | 14                                | 3.1%  |
| Surgery-Related Measures  | 13                                | 2.9%  |
| Immunization-Related Measures                                     | 12                                | 2.6%  |
| Pain-Related Measures   | 11                                | 2.4%  |
| Measures Related to Infections                                    | 10                                | 2.2%  |
| Cost of Care Measures   | 7                                 | 1.5%  |
| Measures Related to Mortality Rates                               | 6                                 | 1.3%  |
| Measures Related to Care Coordination                             | 4                                 | 0.9%  |

Note: All data are as of October 2023, when CMIT data was pulled.

#### Types of Performance Measures

This analysis focuses on the 618 total performance measures across the 24 programs/models (not the 455 distinct performance measures) in order to assess performance measures at the program level.



The CMIT includes seven types of performance measures: process, outcome, intermediate outcome, patient-reported, cost/resource use, structure, and composite measures. **Exhibit 8** provides CMS definitions for these seven measure types, as well as examples of each measure type as listed in the CMIT.

**Exhibit 8.** CMS Definitions of the Seven Performance Measure Types

| Measure Type   | Definition <sup>15</sup>  | Examples   |
|--|---|--|
| Composite Measure  | Two or more measures that form a combined measure   | Severe Sepsis/Septic Shock: Management Bundle; Patient Safety and Adverse Events Composite; Substance Use Screening and Intervention Composite   |
| Cost/Resource Use Measure                                      | Measures the cost or frequency of health care services provided   | Asthma/Chronic Obstructive<br>Pulmonary Disease (COPD)<br>Episode-Based Cost Measure;<br>Medicare Spending per Beneficiary<br>(MSPB); Total Per Capita Cost  |
| Intermediate Outcome Measure                                   | Assesses the change that occurs from treatment resulting in a long-term outcome                         | Controlling High Blood Pressure;<br>Diabetes: Hemoglobin A1c (HbA1c)<br>Poor Control (> 9%); Kidney<br>Transplant Referral Rate  |
| Outcome Measure  | Focuses on the health status of a patient that changes due to care or treatment received                | Acute Care Hospitalization;<br>Unplanned Readmissions for<br>Cancer Patients; Patient Fall   |
| Patient-Reported Outcome-Based<br>Performance Measure (PRO-PM) | Based on patient-reported outcome measure (PROM) data aggregated for the responsible health care entity | Consumer Assessment of<br>Healthcare Providers and Systems<br>(CAHPS); Functional Status<br>Change for Patients with Hip<br>Impairments; Patient-Reported<br>Overall Physical Health Following<br>Chemotherapy |
| Process Measure  | Focuses on the actions to be followed to provide adequate care  | Advance Care Plan; Adult<br>Immunization Status; Osteoporosis<br>Management in Women Who Had<br>a Fracture   |
| Structure Measure  | Evaluates health care organizations related to its ability to provide adequate health care              | Health Screening Rate; Continuity of Care Recall System; Patients Left Without Being Seen  |

Note: All data are as of October 2023, when CMIT data was pulled.


Final | March 2024

\_

<sup>&</sup>lt;sup>15</sup> https://mmshub.cms.gov/about-quality/new-to-measures/types

**Exhibit 9** displays the distribution of performance measures by measure type. Of the 618 performance measures included across the 24 programs/models, more than half of the performance measures (323 measures or 52%) were process measures. Outcome measures were the second most common measure type (26%, n=163); patient-reported measures constitute 9% (n=55); and cost/resource use measures are 6% (n=35). Intermediate outcome, composite, and structure measures constitute only 4%, 2%, and 1% of performance measures, respectively.

**Exhibit 9.** Distribution of Performance Measures by Measure Type for the 24 Programs/Models



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.

**Exhibit 10** provides a breakdown of the 618 total performance measures by program/model and measure type. Most of the 24 programs/models use about three to four different performance measure types. The Merit-based Incentive Payment System (MIPS) Program is the only program that uses six measure types (all except composite measures). No program/model uses all seven measure types. Twenty-two programs/models (92%) – all except KCC and Hospice QR – use outcome or intermediate outcome measures. Nineteen programs/models (79%) use process measures; 15 (63%) use at least



one patient-reported outcome measure; five programs/models (21%) use composite measures. 16 Only three programs/models (12%) use structure measures. 17

Exhibit 10. Distribution of Performance Measures by Program/Model and Measure Type

| Program/<br>Model  | Composite  | Cost/<br>Resource<br>Use | Intermediate<br>Outcome | Outcome     | Patient-<br>Reported | Process      | Structure | Total |
|--|------------|--------------------------|-------------------------|-------------|----------------------|--------------|-----------|-------|
| Merit-based<br>Incentive<br>Payment<br>System (MIPS)<br>Program            | 0 (0%)     | 24<br>(8%)               | 8<br>(3%)               | 43<br>(14%) | 31<br>(10%)          | 201<br>(65%) | 2 (1%)    | 309   |
| Medicare<br>Advantage (MA)<br>Star Ratings                                 | 0<br>(0%)  | 0<br>(0%)                | 1<br>(3%)               | 1<br>(3%)   | 7<br>(21%)           | 24<br>(73%)  | 0<br>(0%) | 33    |
| Bundled Payment for Care Improvement Advanced (BPCI-A)                     | 7<br>(24%) | 0 (0%)                   | 0 (0%)                  | 8<br>(28%)  | 1<br>(3%)            | 13<br>(45%)  | 0 (0%)    | 29    |
| Home Health<br>Quality<br>Reporting (QR)                                   | 0<br>(0%)  | 1<br>(5%)                | 0<br>(0%)               | 12<br>(54%) | 1<br>(5%)            | 8 (36%)      | 0<br>(0%) | 22    |
| End Stage<br>Renal Disease<br>(ESRD) Quality<br>Incentive<br>Program (QIP) | 0 (0%)     | 0 (0%)                   | 6<br>(30%)              | 5<br>(25%)  | 1<br>(5%)            | 7<br>(35%)   | 1<br>(5%) | 20    |
| Long-Term Care<br>Hospital (LTCH)<br>QR                                    | 0<br>(0%)  | 1<br>(6%)                | 0<br>(0%)               | 9 (50%)     | 0<br>(0%)            | 8<br>(44%)   | 0 (0%)    | 18    |
| Skilled Nursing<br>Facility (SNF)<br>Quality<br>Reporting<br>Program (QRP) | 0 (0%)     | 1<br>(6%)                | 0 (0%)                  | 9 (50%)     | 0 (0%)               | 8 (44%)      | 0 (0%)    | 18    |

<sup>&</sup>lt;sup>16</sup> BPCI-A (n=7), IPF QR (n=3), HHVBP (n=2), HQRP (n=2), and HAC Reduction Program (n=1) use composite measures.

<sup>&</sup>lt;sup>17</sup> MIPS (n=2), ESRD QIP (n=1), and Hospital OQR (n=1) use structure measures.



| Program/<br>Model   | Composite  | Cost/<br>Resource<br>Use | Intermediate<br>Outcome | Outcome     | Patient-<br>Reported | Process     | Structure | Total |
|---|------------|--------------------------|-------------------------|-------------|----------------------|-------------|-----------|-------|
| Inpatient<br>Rehabilitation<br>Facility (IRF) QR                                  | 0<br>(0%)  | 1<br>(6%)                | 0<br>(0%)               | 11<br>(61%) | 0<br>(0%)            | 6<br>(33%)  | 0 (0%)    | 18    |
| Hospital Value-<br>Based<br>Purchasing<br>(VBP)                                   | 0 (0%)     | 4<br>(24%)               | 0 (0%)                  | 12<br>(70%) | 1<br>(6%)            | 0 (0%)      | 0 (0%)    | 17    |
| Inpatient<br>Psychiatric<br>Facility (IPF) QR                                     | 3<br>(18%) | 0<br>(0%)                | 0<br>(0%)               | 1<br>(6%)   | 0<br>(0%)            | 13<br>(76%) | 0<br>(0%) | 17    |
| Medicare<br>Shared Savings<br>Program<br>(MSSP)                                   | 0 (0%)     | 0 (0%)                   | 4<br>(25%)              | 3<br>(19%)  | 1<br>(6%)            | 8<br>(50%)  | 0 (0%)    | 16    |
| Prospective Payment System (PPS)- Exempt Cancer Hospital Quality Reporting (CHQR) | 0 (0%)     | 0 (0%)                   | 2<br>(13%)              | 8 (50%)     | 1<br>(6%)            | 5<br>(31%)  | 0 (0%)    | 16    |
| Hospital Outpatient Quality Reporting (OQR)                                       | 0 (0%)     | 0 (0%)                   | 0 (0%)                  | 3 (20%)     | 2<br>(13%)           | 9 (60%)     | 1<br>(7%) | 15    |
| Ambulatory<br>Surgical Center<br>(ASC) QR   | 0<br>(0%)  | 0<br>(0%)                | 0<br>(0%)               | 10<br>(71%) | 2<br>(14%)           | 2 (14%)     | 0<br>(0%) | 14    |
| Home Health<br>VBP (HHVBP)<br>(original)  | 2<br>(25%) | 0<br>(0%)                | 0<br>(0%)               | 5<br>(63%)  | 1<br>(12%)           | 0 (0%)      | 0<br>(0%) | 8     |
| Primary Care<br>First (PCF)<br>Model  | 0<br>(0%)  | 1<br>(14%)               | 2<br>(29%)              | 1<br>(14%)  | 1<br>(14%)           | 2<br>(29%)  | 0<br>(0%) | 7     |



| Program/<br>Model  | Composite  | Cost/<br>Resource<br>Use | Intermediate<br>Outcome | Outcome      | Patient-<br>Reported | Process      | Structure | Total |
|--|------------|--------------------------|-------------------------|--------------|----------------------|--------------|-----------|-------|
| Hospital<br>Acquired<br>Condition (HAC)<br>Reduction<br>Program                                  | 1<br>(17%) | 0 (0%)                   | 0 (0%)                  | 5<br>(83%)   | 0 (0%)               | 0 (0%)       | 0 (0%)    | 6     |
| Hospital<br>Readmission<br>Reduction<br>Program<br>(HRRP)  | 0 (0%)     | 0 (0%)                   | 0 (0%)                  | 6 (100%)     | 0 (0%)               | 0 (0%)       | 0 (0%)    | 6     |
| Independence-<br>at-Home (IAH)<br>Demonstration  | 0<br>(0%)  | 0<br>(0%)                | 0<br>(0%)               | 3<br>(50%)   | 0<br>(0%)            | 3<br>(50%)   | 0<br>(0%) | 6     |
| Oncology Care<br>Model (OCM)   | 0<br>(0%)  | 0<br>(0%)                | 0<br>(0%)               | 2<br>(33%)   | 1<br>(17%)           | 3<br>(50%)   | 0<br>(0%) | 6     |
| Accountable Care Organization (ACO) Realizing Equity, Access, and Community Health (REACH) Model | 0 (0%)     | 0 (0%)                   | 0<br>(0%)               | 3 (60%)      | 1 (20%)              | 1 (20%)      | 0 (0%)    | 5     |
| Kidney Care<br>Choices (KCC)<br>Model  | 0<br>(0%)  | 2<br>(40%)               | 0<br>(0%)               | 0<br>(0%)    | 2<br>(40%)           | 1<br>(20%)   | 0<br>(0%) | 5     |
| Hospice QRP<br>(HQRP)  | 2<br>(50%) | 0<br>(0%)                | 0<br>(0%)               | 0<br>(0%)    | 1<br>(25%)           | 1<br>(25%)   | 0<br>(0%) | 4     |
| Skilled Nursing<br>Facility (SNF)<br>VBP   | 0 (0%)     | 0<br>(0%)                | 0<br>(0%)               | 3<br>(100%)  | 0<br>(0%)            | 0 (0%)       | 0<br>(0%) | 3     |
| Total  | 15<br>(2%) | 35<br>(6%)               | 23<br>(4%)              | 163<br>(26%) | 55<br>(9%)           | 323<br>(52%) | 4<br>(1%) | 618   |


Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.



#### Sources of Performance Measures

The CMIT includes eight performance measure data sources: registries, claims data, electronic clinical data (non-EHR), electronic health records (EHRs), paper medical records, standardized patient assessments, administrative data (non-claims), and patient-reported data and surveys. Of the 618 performance measures included among the 24 programs/models, data sources were spread across the eight different sources. Registry data are the most common performance measure data source used among the 24 models/programs accounting for 24% of measures (n=229). Data sources are not specified in the CMIT for 1% (n=5) of performance measures. **Exhibit 11** provides the distribution of performance measures by data source. There often are multiple data sources used for a given performance measure; accordingly, Exhibit 11 reflects a total n of 964 (as opposed to 618).

**Exhibit 11.** Distribution of Performance Measures by Data Sources for the 24 Programs/Models



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.


#### Measure Reporting Level

Of the 618 performance measures included among the 24 programs/models, 31% (n=191) of the measures are reported at the facility, hospital, or agency level; 28% (n=176) are reported at the



clinician group practice level. About 28% (n=173) of performance measures do not specify level of reporting. **Exhibit 12** provides the distribution of performance measures by reporting level. Reporting level was created using the column "Level of Analysis" from the CMIT.

Exhibit 12. Distribution of Performance Measures by Reporting Level for the 24 Programs/Models



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.

#### Performance Measure Endorsement Status

The CMIT includes information on whether the performance measure is endorsed by the CMS Consensus-Based Entity (CBE). <sup>18</sup> **Exhibit 13** provides the endorsement status for the 618 performance measures associated with the 24 programs/models. About 34% (n=209) of performance measures are endorsed, 59% (n=366) of measures are not endorsed, and endorsement has been removed for 7% (n=42). Twenty-three programs/models have at least one endorsed measure; the MA Star Ratings is

Final | March 2024


-

<sup>&</sup>lt;sup>18</sup> Battelle's Partnership for Quality Measurement (PQM) currently serves as the CMS CBE. See <a href="https://mmshub.cms.gov/sites/default/files/Blueprint-CMS-CBE-Endorsement-Maintenance.pdf">https://mmshub.cms.gov/sites/default/files/Blueprint-CMS-CBE-Endorsement-Maintenance.pdf</a> and <a href="https://p4qm.org/about">https://p4qm.org/about</a> for more information on the CMS CBE process.



the only program without any endorsed measures. For two programs – Hospital Acquired Condition Reduction Program (HACRP) and Hospital Readmission Reduction Program (HRRP) – all active performance measures are endorsed (six measures each).

Exhibit 13. Distribution of Performance Measures by Endorsement Status for 24 Programs/Models



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with to the OCM are inactive measures.

#### Whether Performance Measures are Tied to Payment

The 24 programs/models were categorized as pay-for-performance, pay-for-reporting, or not related to payment based on information from the CMS program and CMMI Innovation Models websites. <sup>19</sup> **Exhibit 14** provides the program/model type as it relates to payment for the 24 programs/models. Fifteen programs/models (63%)<sup>20</sup> were characterized as pay-for-performance, defined as programs/models whose focus is on providing payment to providers based on outcomes of patients;


<sup>&</sup>lt;sup>19</sup> https://www.cms.gov/priorities/innovation/models#views=models

<sup>&</sup>lt;sup>20</sup> Pay-for-performance programs/models include ACO REACH, BPCI-A, ESRD QIP, HACRP, HHVBP, Hospital VBP, HRRP, IAH Demonstration, KCC Model, MA Star Ratings Program, MIPS, MSSP, OCM, PCF Model, and SNF VBP.



providing better outcomes results in higher payments.<sup>21</sup> Eight programs/models (33%)<sup>22</sup> were characterized as pay-for-reporting, defined as programs/models that are required to report quality measure data to CMS and result in a decrease to Medicare payments for nonperformance.<sup>23</sup> One program (4%), the PPS-Exempt CHQR, does not currently tie performance measures to payment.

Exhibit 14. Distribution of the 24 Programs/Models by Relationship to Provider Payment



The 15 pay-for-performance programs/models may also be characterized as another type of program, as defined on CMS program and CMMI Innovation Models websites. For example, four pay-for-performance programs/models were also characterized as disease-specific and episode-based programs/models: BPCI-A, ESRD QIP, HHVBP, and OCM. Also, four pay-for-performance programs/models use the term value-based purchasing to define their program/model: HACRP, Hospital VBP, HRRP, and SNF VBP. Three pay-for-performance models – ACO REACH, KCC, and PCF – are also considered Accountable Care Organizations (ACOs). The IAH Demonstration, a pay-for-performance model, is also defined as a statutory model. The PPS-Exempt CHQR Program, which

<sup>21</sup> https://www.cms.gov/regulations-and-guidance/guidance/faca/downloads/tab h.pdf

<sup>&</sup>lt;sup>22</sup> Pay-for-reporting programs include ASCQR, Home Health QR, Hospital OQR, HQRP, IPFQR, IRFQR, LTCH QR, and SNF QRP.

<sup>&</sup>lt;sup>23</sup> <a href="https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HomeHealthQualityInits/Downloads/Pay-for-Reporting-Quality-Assessments-Only-Methodology.pdf">https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HomeHealthQualityInits/Downloads/Pay-for-Reporting-Quality-Assessments-Only-Methodology.pdf</a>



does not currently tie performance measures to payment, is considered a quality reporting program (as opposed to pay-for-reporting). **Exhibit 15** provides definitions for all programs/model types.

Exhibit 15. Program/Model Type Definitions

| Program/Model Type                 | Definition  |
|------------------------------------|---|
| Accountable Care                   | Models in which a doctor, group of health care providers or hospital takes financial responsibility for improving quality of care, including advanced primary care services, care coordination and health outcomes for a defined group of patients, thereby reducing uncoordinated care and unnecessary costs for patients and the health system. <sup>24</sup> |
| Disease-Specific and Episode-Based | Models which aim to address deficits in care for a defined population with a specific shared disease or medical condition, procedure, or care episode. <sup>25</sup>  |
| Pay-for-Performance                | Programs/models whose focus is on providing payment to providers based on outcomes of patients; providing better outcomes results in higher payments. <sup>26</sup>   |
| Pay-for-Reporting                  | Programs/models that are required to report quality measure data to CMS and result in a decrease to Medicare payments for nonperformance. <sup>27</sup>   |
| Quality Reporting                  | Programs/models are required to report on certain quality measures; however, measures are not necessarily tied to payment.  |
| Statutory Models                   | Models and demonstrations requiring testing as determined by Congress and/or the Secretary of Health and Human Services. <sup>28</sup>  |
| Value-Based Purchasing             | Programs/models that reward providers with incentive payments for the quality of care they provide to Medicare beneficiaries. <sup>29</sup>   |

NORC also examined the distribution of the 618 performance measures based on how the 24 programs/models are linked with payment (**Exhibit 16**).<sup>30</sup> Seventy-seven percent (n=476) of the measures correspond with the 15 pay-for-performance programs/models (50% [n=309] are MIPS performance measures, while the remaining 27% [n=167] correspond to the other 14 pay-for-performance programs/models). Twenty percent (n=126) of the measures correspond with the eight

Final | March 2024

2

<sup>&</sup>lt;sup>24</sup> https://www.cms.gov/priorities/innovation/models#views=models

<sup>&</sup>lt;sup>25</sup> https://www.cms.gov/priorities/innovation/models#views=models

<sup>&</sup>lt;sup>26</sup> https://www.cms.gov/regulations-<u>and-guidance/guidance/faca/downloads/tab\_h.pdf</u>

<sup>27</sup> https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HomeHealthQualityInits/Downloads/Pay-for-Reporting-Quality-Assessments-Only-Methodology.pdf

<sup>&</sup>lt;sup>28</sup> https://www.cms.gov/priorities/innovation/models#views=models


<sup>&</sup>lt;sup>29</sup> https://www.cms.gov/medicare/guality/value-based-programs

<sup>&</sup>lt;sup>30</sup> There are some limitations of this analysis, including 1) not all measures for a given program/model are necessarily tied to payment or required to be reported (e.g., some programs/models have many measures from which providers choose a set of measures); 2) measure-specific requirements can change frequently; and 3) measures may be used differently in different programs/models.



pay-for-reporting programs, and three percent of the measures correspond with the one program (PPS-Exempt CHQR) that is not linked with payment.

**Exhibit 16.** Distribution of Performance Measures Based on How the 24 Selected Programs/Models are Linked with Payment



Note: Performance measures include active, in-development, pending, and suspended measures listed in the CMIT as of October 2023. Further, the OCM is an inactive model; the six measures associated with the OCM are inactive measures.

Note: There are some limitations of this analysis, including 1) not all measures for a given program/model are necessarily tied to payment or required to be reported (e.g., some programs/models have many measures from which providers choose a set of measures); 2) measure-specific requirements can change frequently; and 3) measures may be used differently in different programs/models.

## Analysis 2: How Performance Measures are Tied to Payment

This second analysis focuses on 18 selected programs/models (14 CMMI models and four CMS value-based programs) (refer to Exhibit 1). Information on whether and how performance measures are tied to payment was obtained by reviewing CMS program and CMMI Innovation Model websites.<sup>31</sup>

Final | March 2024

-

<sup>&</sup>lt;sup>31</sup> The available information on each of the 14 selected CMMI models' summary pages on the Innovation Center website was reviewed (<a href="https://www.cms.gov/priorities/innovation/models#views=models">https://www.cms.gov/priorities/innovation/models#views=models</a>). Information found in these materials was used to summarize the models' main themes related to performance measurement and other administrative and payment characteristics.

A detailed review of the BPCI-A model was performed to provide an example of how performance measures are tied to payment. Participants in the BPCI-A model have the option of selecting either the Administrative Quality Measure (QM) set, or the Alternative QM set for a given clinical episode category. For each clinical episode, the Administrative QM set includes:

- 1) The following two measures:
  - Hospital-Wide All Cause Readmission (NQF #1789)
  - Advance Care Plan (NQF #0326); and
- 2) Up to two of the following additional measures:
  - Excess days in acute care after hospitalization for AMI (NQF #2881)
  - Risk-Standardized Mortality Rate CABG Surgery (NQF #2558)
  - Hospital-level Risk-Standardized Complication Rate Following Elective Primary THA and/or TKA (NQF #1550)
  - CMS Patient Safety Indicators PSI 90 (NQF#0531).

For each clinical episode, the Alternative QM set includes:

- 1) The following two measures:
  - Hospital-Wide All Cause Readmission (NQF #1789)
  - Advance Care Plan (NQF #0326); and
- 2) Up to three additional measures (including claims-based and registry-based measures).

Reconciliation is based on comparing actual Medicare FFS expenditures for all items and services included in a clinical episode with the final total price for that episode. At reconciliation, CMS determines whether participants receive a payment or are required to pay a repayment amount.

Participants receive a Composite Quality Score (CQS) based on the applicable quality measures for the clinical episode. CMS uses the CQS to apply an adjustment amount of up to 10% for the total reconciliation amounts. **Exhibit 17** summarizes how performance measures are linked with payment in the BPCI-A model.



Exhibit 17. Performance-Based Payment Example: BPCI-A Model

#### **Composite Quality Score Model Overview** Reconciliation (CQS) **Administrative Quality Measure Set** Voluntary episode-based · Actual expenditures are (6 claims-based measures) bundled payment model compared with the final TP 2 measures for all episodes for the episode. • 30+ clinical episode (Readmissions, Advance Care Plan) categories · CMS determines whether · Up to 2 additional measures participants receive a · Participants receive a payment or are required to preliminary target price (TP) OR pay a repayment amount based on Medicare FFS expenditures for all items and **Alternative Quality Measure Set** • The positive or negative services included in each · 2 measures for all episodes total reconciliation amount clinical episode (Readmissions, Advance Care Plan) is adjusted by up to 10% Up to 3 additional measures based on the CQS Final TP is adjusted at (including claims-based and registry-

**Exhibit 18** provides detailed payment information on the 18 programs/models. All 18 models and programs adjust payment based on performance. Thirteen (72%) models and programs employ both upside and downside risk for participants. The MCP, IAH, CPC+, and OCM models and the MA Star Ratings Program employ upside risk only.

based measures)

Exhibit 18. Payment Information for 18 Programs/Models

| Model   | Whether<br>Payment is Tied<br>to Performance | Risk              | How Payment is Tied to Performance  |
|---|--|-------------------|---|
| Accountable Care<br>Organization (ACO)<br>Realizing Equity,<br>Access, and<br>Community Health<br>(REACH) | Yes  | Upside & downside | CMS calculates the total cost of care at the end of the performance year. If the payments and additional feefor-service (FFS) Medicare expenditures exceed the performance year benchmark, the ACO repays CMS the shared losses according to its risk sharing arrangement; otherwise, CMS pays shared savings to the ACO. Advanced Payment Option (APO) payments are also reconciled in a similar manner. In addition, 2% of an ACO's financial benchmark is held at risk; ACOs can earn part or all depending on their Initial Quality Score (IQS) based on four quality measures. |

reconciliation



| Model   | Whether<br>Payment is Tied<br>to Performance | Risk              | How Payment is Tied to Performance   |
|---|--|-------------------|--|
| Bundled Payments<br>for Care<br>Improvement<br>Advanced (BPCI-A)      | Yes  | Upside & downside | Participants receive a retrospective bundled payment or are required to pay a Repayment Amount based on reconciliation against the benchmark/target price.  Participants receive a Composite Quality Score (CQS) based on selected quality measures, and payment is adjusted by up to 10% for positive reconciliation amounts (where participant receives a payment) or negative reconciliation amounts (where participant is required to pay back).   |
| Comprehensive<br>ESRD Care (CEC)<br>Model                             | Yes  | Upside & downside | The CEC Operations Contractor calculates the Shared Savings or Shared Losses at the end of each performance year. If the ESCO meets or exceeds the Total Performance Score (TPS) minimum level of attainment and the Total Quality Score (TQS) minimum level of attainment (in PY1) or the TQS minimum performance threshold (in PY2 onward), CMS multiplies the total Medicare savings or losses by the ESCO TQS to determine the preliminary shared savings or preliminary shared losses payments. |
| Comprehensive<br>Primary Care Plus<br>(CPC+) Model                    | Yes  | Upside only       | Practices receive performance-based incentive payments (PBIPs) based on patient experience, clinical quality, and utilization; practices retain all or a portion of the PBIP based on performance. The PBIP is paid prospectively for the entire subsequent year based on the prior year's performance. Practices that do not meet the annual performance thresholds for clinical quality/patient experience or utilization are "at risk" for repaying all or a portion of the PBIP.                 |
| Enhancing Oncology<br>Model (EOM)                                     | Yes  | Upside & downside | Retrospective performance-based payment (PBP) or performance-based recoupment (PBR) based on quality and savings during the performance period (i.e., six-month episodes of care).   |
| End-Stage Renal<br>Disease (ESRD)<br>Treatment Choices<br>(ETC) Model | Yes  | Upside & downside | Participants receive a home dialysis payment adjustment (HDPA) and a performance payment adjustment (PPA). Medicare claim payments are increased for facilities and clinicians supporting dialysis at home, and PPAs are either increased or decreased based on the rate of home dialysis and transplant rate, calculated as the sum of the transplant waitlist rate and the living donor transplant rate.   |



| Model   | Whether<br>Payment is Tied<br>to Performance | Risk              | How Payment is Tied to Performance  |
|---|--|-------------------|---|
| Expanded Home<br>Health Value-Based<br>Purchasing<br>(Expanded HHVBP) | Yes  | Upside & downside | Home health agencies receive adjustments to their FFS payments based on their TPS, a composite score of an agency's quality measures, relative to peers' performance. Performance on quality measures impacts payment adjustments in a later year.  |
| Home Health Value-<br>Based Purchasing<br>(HHVBP)                     | Yes  | Upside & downside | Medicare payments are adjusted upward or downward by up to 3%, 5%, 6%, or 7% based on the TPS, a composite score of an agency's quality achievement/improvement on the measure set and the performance year.  |
| Hospital Value-<br>Based Purchasing<br>(Hospital VBP)                 | Yes  | Upside & downside | 2% of participants' payments are withheld; this total amount is used to fund value-based incentive payments to hospitals based on their performance. Participants' payments are adjusted based on a total performance score.  |
| Independence at<br>Home (IAH)<br>Demonstration                        | Yes  | Upside only       | Practices can receive 50% of shared savings for meeting/exceeding performance requirements on three measures, 66.7% of shared savings for four measures, 83.3% for five measures, and 100% for all six measures.  |
| Kidney Care Choices<br>(KCC) Model                                    | Yes  | Upside & downside | The KCC model offers different payment mechanisms, including the Kidney Care First (KCF) Option (i.e., adjusted capitated payments based on performance on quality measures, health outcomes, and utilization; bonus payments for successful kidney transplants); the Kidney Contracting Entities (KCEs) Option (i.e., adjusted capitated payments; shared savings based on spending and quality measures), which includes the Comprehensive Kidney Care Contracting (CKCC) Graduated Option (i.e., one-sided risk track); the CKCC Professional Option (i.e., share in 50% of earnings or losses); and the CKCC Global Option (i.e., share in 100% of earnings or losses). |
| Making Care Primary<br>(MCP) Model                                    | Yes  | Upside only       | Participants are eligible to receive upside-only<br>Performance Incentive Payments (PIP) that reward<br>participants for improving patient health outcomes and<br>achieving savings.  |
| Medicare Advantage<br>(MA) Star Ratings<br>Program                    | Yes  | Upside only       | Participants receive a performance-based bonus payment if they obtain a 4-, 4.5-, or 5-Star Rating.   |



| Model  | Whether<br>Payment is Tied<br>to Performance | Risk              | How Payment is Tied to Performance  |
|--|--|-------------------|---|
| Medicare Shared<br>Savings Program<br>(MSSP)                 | Yes  | Upside & downside | Participants must meet a series of quality thresholds to receive shared savings; ACOs are subject to quality withholds from their shared savings if they do not meet quality benchmarks.  |
| Merit-based<br>Incentive Payment<br>System (MIPS)<br>Program | Yes  | Upside & downside | Performance is measured across 4 domains; participants' final scores determine the payment adjustment applied to their claims.  |
| Next Generation<br>ACO (NGACO)                               | Yes  | Upside & downside | ACOs participate in shared savings or losses based on performance year expenditures. ACOs may receive an Earned Quality Bonus for meeting quality requirements. CMS uses a quality "withhold," in which a portion of an ACO's performance year benchmark is held "at-risk," contingent upon the ACO's quality score.                                    |
| Oncology Care<br>Model (OCM)                                 | Yes  | Upside only       | The amount of the performance-based payment is adjusted based on the participant's achievement on a range of quality measures. Once quality points are assigned, an Aggregate Quality Score (AQS) is calculated and translated into a performance multiplier. This performance multiplier is used as part of the performance-based payment calculation. |
| Primary Care First<br>(PCF) Model                            | Yes  | Upside & downside | A practice's payment amount depends on its performance compared to peer practices and its degree of improvement compared to its historical performance. Performance-based payment can be up to a 50% increase or a 10% decrease in total primary care payment revenue.  |



#### Analysis 3: Gaps in Current Performance Measures

This third analysis also focuses on the 18 programs/models (14 models and four programs) (refer to Exhibit 1). Information on potential gaps in current performance measures was obtained by reviewing publicly available evaluation reports. Various performance measure gaps have been identified in the assessment of the evaluation reports relating to for these programs and models. Concerns that were identified range from the need to have increased financial incentives linked to performance measures to challenges related to the lack of specificity in certain measures. The following are some additional highlights of findings from this analysis.

- Few CMMI models incorporated guardrails to prevent unintended consequences, such as
  worsening disparities. One exception is the ETC Model, which includes a Health Equity
  Incentive that provides additional improvement points to participants who show improvement in
  the home dialysis rate or transplant rate for their attributed dual-eligible or Low Income Subsidy
  (LIS) beneficiaries.
- Evaluation reports identify the importance of guardrails to prevent unintended consequences within models.
- An evaluation identified performance gaps within the Home Health Value-Based Purchasing (HHVBP) Program suggesting potential disparities in health equity. Over time, a pronounced widening gap between patients with and without Medicaid in HHVBP states raised alarms about persisting quality gaps. The report emphasized the need for targeted initiatives to prevent unintended consequences and to address pre-existing disparities.

Appendix C and Appendix D provide additional information on potential gaps, issues, and concerns related to current performance measures across the 18 selected programs/models.



### Appendix A. Methodology

#### Analyses and Data Sources

Three types of analyses were conducted using the following data sources:

- 1) Performance measure-level analysis for 24 selected programs/models using the CMS Measures Inventory Tool (CMIT). This analysis provides the following descriptive information about the performance measures included in these programs/models:
- · Total performance measures
- Unique performance measures
- · Measures focused on similar aspects of care
- · Types of performance measures
- · Sources of performance measures
- Measure reporting level
- · Performance measure endorsement status
- Whether performance measures are tied to payment<sup>32</sup>

The CMIT is a repository of performance measure information that includes 46 federal CMS value-based care programs or models (as of October 2023 when CMIT data were pulled). For each measure, the CMIT includes program/model name, measure name, measure definition, measure type, and measure source. Information from the CMIT was available for 24 of the 31 selected programs/models; seven models are not part of the CMIT. The supplemental Excel file (2023 Performance Measure Data for 24 CMS Models and Programs) contains three tabs. The first tab provides a description of the data included in the second tab of the supplemental Excel file. The second tab provides performance measure-level information obtained for the 24 programs/models pulled from the CMIT or from CMS/CMMI websites; the third tab provides a data dictionary that includes the column name, data sources, column name from the CMIT, definition, and whether the column is a CMIT required field. See Appendix B for additional information on the 2023 Performance Measure Data for 24 CMS Models and Programs supplemental Excel file.

<sup>&</sup>lt;sup>32</sup> The CMIT variable related to identifying if performance on a given measure is tied to payment for the applicable program/model is not a required field, and CMIT does not specify if performance is tied to payment for 60% (n=373) of the 618 performance measures identified in this analysis. This is a limitation of CMIT. Therefore the 24 selected programs/models were categorized as pay-for-performance, pay-for-reporting, or not related to payment based on information from the CMS website or the CMMI Innovation Models webpage.

<sup>&</sup>lt;sup>33</sup> Centers for Medicare & Medicaid Services Measures Inventory Tool, <a href="https://cmit.cms.gov/cmit/#/MeasureInventory">https://cmit.cms.gov/cmit/#/MeasureInventory</a>

<sup>&</sup>lt;sup>34</sup> The seven models not included in the CMIT are the Comprehensive End Stage Renal Disease (ESRD) Care (CEC) Model, Comprehensive Primary Care Plus (CPC+) Model, Enhancing Oncology Model (EOM), ESRD Treatment Choices (ETC) Model, Expanded Home Health Value-Based Purchasing (HHVBP) Model, Making Care Primary (MCP) Model, and the Next Generation Accountable Care Organization (NGACO) Model.



- 2) The second analysis focuses on assessing whether and how performance measures are linked with payment using information obtained from CMS program and CMMI Innovation Model websites. The report includes tables for the 14 selected CMMI models and four CMS programs (out of the 17 programs referenced in Exhibit 1) that describe how performance measures are linked with payment.
- 3) The third analysis provides information on potential gaps in current performance measures using information obtained from publicly available evaluation reports for the 14 CMMI models and four programs.

Appendix C and Appendix D provide detailed payment information and potential gaps in current performance measures, as applicable, for the 18 programs/models (compiled in October 2023).

Appendix E provides a full list of all programs/models included in the analyses.

#### **Program Selection**

A total of 31 models and programs were selected for these analyses: 17 CMS federal value-based care programs (including 9 CMS value-based care programs, 8 CMS pay-for-reporting programs) and 14 CMMI models. The CMS programs (17) were selected to ensure a variety of federal reporting programs (e.g., pay-for-performance, pay-for-reporting, quality reporting and other approaches). The CMMI models (14) were selected based on the following criteria: 1) the model must have been active in the last five years; 2) the model must include at least one quality measure and at least one utilization or spending measure in implementation and/or monitoring; and 3) the model must be or have been operational in more than one state.



# Appendix B. Detailed Performance Measure-Level Information Based on an Analysis of Data from the CMIT for 24 Selected Medicare Programs/Models

A detailed performance measure-level analysis was conducted for 24 selected programs/models using data from the CMS Measures Inventory Tool (CMIT). The following is a list of the 24 Medicare programs/models that are included in this analysis.

- Accountable Care Organization (ACO) Realizing Equity, Access, and Community Health (REACH) Model
- Ambulatory Surgical Center (ASC) Quality Reporting Program (QRP)
- Bundled Payment for Care Improvement Advanced (BPCI-A) Model
- End-Stage Renal Disease (ESRD) Quality Incentive Program (QIP)
- Home Health Quality Reporting (QR)
- Home Health Value-Based Purchasing (HHVBP) (original)
- Hospice Quality Reporting Program (HQRP)
- Hospital Acquired Condition (HAC) Reduction Program
- Hospital Outpatient Quality Reporting (OQR) Program
- Hospital Readmission Reduction Program (HRRP)
- Hospital Value-Based Purchasing (VBP)
- Independence at Home (IAH) Demonstration
- Inpatient Psychiatric Facility (IPF) Quality Reporting Program (QRP)
- Inpatient Rehabilitation Facility (IRF) Quality Reporting Program (QRP)
- · Kidney Care Choices (KCC) Model
- Long-Term Care Hospital (LTCH) Quality Reporting Program (QRP)



- Medicare Advantage (MA) Star Ratings Program
- Medicare Shared Savings Program (MSSP)
- Merit-Based Incentive Payment System (MIPS) Program
- Oncology Care Model (OCM)
- Primary Care First (PCF) Model
- Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting (CHQR) Program
- Skilled Nursing Facility (SNF) Quality Reporting Program (QRP)
- Skilled Nursing Facility (SNF) Value-Based Purchasing (VBP)

**Exhibit B.1** lists the information that is included for each performance measure in the supplemental Excel File. The Supplemental Excel File (2023 Performance Measure Data for 24 CMS Models and Programs) can be accessed on the <u>PTAC Resources webpage</u>.



**Exhibit B1.** Detailed Information for Each Performance Measure in the 2023 Performance Measure Data for 24 CMS Models and Programs Supplemental Excel File

| Column Name                                    | Data Source | Column Name<br>from CMIT           | <b>Definition</b> <sup>a</sup>  |
|--|-------------|------------------------------------|---|
| Program/Model Name                             | CMIT        | Program                            | The CMS Program which uses this program-specific version as designated by legislation, rule or policy.  |
| Program/Model Type as it<br>Relates to Payment | non-CMIT    |                                    | The 24 programs/models were categorized as pay-for-performance, pay-for-reporting, or not related to payment based on information from the CMS website or the CMMI Innovation Models webpage.   |
| Measure ID                                     | CMIT        | Measure ID                         | Unique ID attached to a measure.  |
| Measure Variation ID                           | CMIT        | Measure Variation ID               | ID representing a form of a measure with a specification that differentiates it from others that are similar. <sup>b</sup>  |
| Measure Name                                   | CMIT        | Program-Specific<br>Measure Titles | The title of a program-specific version derived from a measure.   |
| Measure Type                                   | CMIT        | Measure Type                       | Refers to the domain of quality that a measure assesses.  |
| Measure Reporting Status                       | CMIT        | Reporting Status                   | Indicates if a program is active, pending, in development, suspended, or inactive.  |
| Measure Definition                             | CMIT        | Description                        | Briefly describe the type of score (e.g., percentage, percentage rate, proportion, number), target population, and focus of measurement in this format: "The percentage of [gender qualifier] if applicable (e.g., "female") patients or individuals during visit or event [environment qualifier](e.g., admitted to a post-anesthesia care unit[PACU]) [age qualifier] (e.g., aged 18 years and older) [denominator definition] (e.g., who are under the care of an anesthesia practitioner) [numerator criteria] (e.g., in which a formal post-anesthetic transfer of care protocol or checklist is used that includes key transfer of care elements)." |
| Measure Data Source                            | CMIT        | Data Sources                       | Data sources are the primary source document(s) used for data collection (e.g., billing or administrative data, encounter form, enrollment forms, patient medical record).  |



| Column Name                             | Data Source | Column Name<br>from CMIT  | <b>Definition</b> <sup>a</sup>   |
|---|-------------|---------------------------|--|
| Measure Reporting Level                 | CMIT        | Level of Analysis         | The level of analysis is a performance measurement level (e.g., clinician, health plan, county populations).   |
| Measure Only Used for One Program/Model | non-CMIT    |                           | This column was categorized by identifying measures in the CMIT for the 24 programs/models that were used exclusively by only one of the 24 programs/models (based on an analysis of measure names).                   |
| Measure Specific Conditions             | CMIT        | Conditions                | A disease, illness or injury including physiologic, mental or psychological disorder (e.g., Cardiovascular Disease, Malignant Neoplasm).   |
| Additional Program/Model<br>Type        | non-CMIT    |                           | Program/model type was created using classifications for the 24 programs/models as described on the CMS website or the CMMI Innovation Models webpage (https://www.cms.gov/priorities/innovation/models#views=models). |
| CMS CBE Endorsement Status              | CMIT        | CBE Endorsement<br>Status | Identifies if the program-specific version has been endorsed by a Consensus Based Entity.  |

<sup>&</sup>lt;sup>a</sup> With the exceptions of the Measure Only Used for One Program/Model and Program/Model Type columns, definitions are from the CMIT Data Dictionary (file: 'Simplified CMIT Data Dictionary Shared' provided by the CMIT helpdesk [mmssupport@battelle.org])

<sup>&</sup>lt;sup>b</sup> Measure Variation ID was not included in the CMIT Data Dictionary supplied; this information was derived from the CMIT Quick Start Guide on their website (https://cmit.cms.gov/cmit/assets/CMIT-QuickStartPublicAccess.pdf)



## Appendix C. Detailed Information on Current Performance Measures for 14 Selected CMMI Models

Exhibit C1. Program Description, Technical Issues, and Gaps Related to Current Performance Measures

| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|--|--|---|---|---|
| Bundled Payments for Care Improvement Advanced (BPCI-A) Ongoing Years active: 2018-present | Clinical Focus: Cross-clinical focus  Providers: Acute care hospitals, physician group practices, Medicare- enrolled providers, ACOs Setting: Inpatient and outpatient services Patient Population: Medicare beneficiaries with certain clinical episodes (29 inpatient, 3 outpatient) | Utilization measure(s): N/A  Quality measure(s): Administrative Quality Measures Set: All-Cause Unplanned Hospital Readmission; Advance Care Plan; CMS Patient Safety and Adverse Events Composite (CMS PSI 90); Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction; Hospital-Level Risk- Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty; Risk- Standardized Mortality Rate Following Coronary Artery Bypass Graft Surgery (CABG) | How payment is adjusted for performance: Participants, called Episode Initiators (IEs), receive a retrospective bundled payment or are required to pay a Repayment Amount based on reconciliation against the benchmark/target price. Further, Els receive a Composite Quality Score (CQS) based on selected quality measures and payment is adjusted by up to 10% for positive reconciliation amounts (where El receives a payment) or negative reconciliation amounts (where El is required to pay back).  Requirements: Participants are required to select the Administrative Quality Measures Set or the Alternate Quality Measures Set at the beginning of each Model Year. | Measures used for implementation: Administrative or Alternate Quality Measures Sets based on the EI selections Measures used for monitoring: All listed measures, as applicable How achievement is measured: Payment is adjusted by up to 10% based on the CQS How improvement is measured: Each Participant's performance is scored based on the Participant's placement in the performance distribution from the baseline year. | N/A   |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|--|--|---|
|                        |   | Alternate Quality Measures Set: All-Cause Unplanned Hospital Readmission; Advance Care Plan; Hospital-Level Risk-Standardized Complication Rate Following Elective Primary Total Hip Arthroplasty; 3- Item Care Transition Measure (CTM-3); Atrial Fibrillation and Atrial Flutter; Bariatric Surgery Standards for Successful Programs Measure; Cardiac Rehabilitation Patient Referral from an Inpatient Setting; Defect Free Care for Acute Myocardial Infarction; Discharge Medications in Eligible Implantable Cardioverter- Defibrillator/Cardiac Resynchronization Therapy Defibrillators Implant Patients; Heart Failure: ACE Inhibitor or ARB or ARNI Therapy for Left Ventricular Systolic Dysfunction (LVSD); Heart Failure: Beta-Blocker Therapy for LVSD; Risk- | Two measures (All-Cause Hospital Readmission and Advance Care Plan) apply to both Measures Sets and are required; participants must select two additional quality measures from the Administrative Quality Measures Set or three additional measures from the Alternate Quality Measures Set to be scored on. Scores result in a CQS which is tied to payment.  Attribution: CMS attributes a Clinical Episode to one El. Clinical Episodes are attributed to Els based on the PGP that submits a claim that includes the physician's NPI or the Acute Care Hospital (ACH) where the services that triggered the Clinical Episode were rendered. A Clinical Episode were rendered. A Clinical Episode on the start of an inpatient admission or outpatient procedure (MS-DRG codes are used to identify qualifying inpatient admissions and HCPCS codes are used to identify qualifying procedures) and ends 90 days after the day |  |   |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|---|---|--|---|
|                        |   | Standardized Mortality Rate Following Pneumonia Hospitalization; Hospital Risk-Standardized Complication Rate following Implantation of ICD Composite Measure; In-Person Evaluation Following Implantation of a Cardiovascular Implantable Electronic Device; Patient-Centered Surgical Risk Assessment and Communication; Preventive Care and Screening: Tobacco Use Screening and Cessation Intervention; Risk Standardized Bleeding for Patients Undergoing Percutaneous Coronary Intervention; Severe Sepsis and Septic Shock: Management Bundle Measure; Discharged on Statin Medication; STS Coronary Artery Bypass Graft Composite Score; Substance Use Screening and Intervention Composite; Therapy with Aspirin, P2Y Inhibitor, and Statin at Discharge | of discharge from hospital or completion of outpatient procedure.  Volume: An entity (EI) must have a minimum of 10 attributed Clinical Episodes to generate a quality score  Risk stratification or adjustment: CMS employs a risk adjustment model that adjusts target prices based on hierarchical condition categories (HCC), HCC interactions, HCC severity, recent resource use, demographics, long-term institutional care, dementia, MS-DRGS/APCs, clinical episode category specific adjustments, and COVID-19 infection rate.  Benchmarking: CMS calculates a Benchmark Price based on historical data to account for variation in costs. |  |   |



| Program/<br>Model Name  | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population                              | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable                           |
|---|--|--|--|--|---|
|   |  | Following Percutaneous Coronary Intervention in Eligible Patients; Time to Intravenous Thrombolytic Therapy; Volume Weighted Aortic Valve Replacement and Aortic Valve Replacement + CABG Composite Measures; Volume Weighted Mitral Valve Repair and Replacement and Mitral Valve Repair and Replacement + CABG Composite Measures  Spending measure(s): All costs of care provided to a Medicare beneficiary during a clinical episode  Patient experience measure(s): Patient- reported care experiences and satisfaction with care |  |  |   |
| Comprehensive<br>ESRD Care<br>(CEC) Model<br>No longer active<br>Years active:<br>2015-2021 | Clinical Focus: End-stage renal disease (ESRD)  Providers: Nephrologists; ESRD Seamless Care | Utilization measure(s): N/A  Quality measure(s): diabetes care (eye exam & food exam), advance care plan, medication reconciliation post-discharge, influenza  | How payment is adjusted for performance: the CEC Operations Contractor calculates the Shared Savings or Shared Losses at the end of each performance year. If the ESCO met or exceeds the TPS minimum levels of attainment | Measures used for implementation: CEC total quality score (TQS) and ESRD QIP total performance score (TPS) | Benchmarks for<br>future models can<br>be reexamined to<br>increase likelihood<br>of net savings. |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population   | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|---|---|---|---|
|                        | Organizations (ESCOs) <sup>35</sup> Setting: Nephrology clinics  Patient Population: Medicare beneficiaries with ESRD | immunization for the ESRD population, pneumococcal vaccination status, screening for clinical depression and follow-up plan, tobacco use: screening and cessation, falls: screening, risk assessment and plan of care to prevent future falls, bloodstream infection in hemodialysis outpatients, hemodialysis adequacy, proportion of patients with hypercalcemia, peritoneal dialysis adequacy: delivered dose of peritoneal dialysis above minimum, hemodialysis vascular access: maximizing placement of arterial venous fistula, hemodialysis vascular access: minimizing use of catheters as chronic dialysis access, standardized hospitalization ratio for admissions, standardized | and the TQS minimum level of attainment (in PY1) or the TQS minimum performance threshold (in PY2 onward), CMS multiplies the total Medicare savings or losses by the ESCO TQS to determine the preliminary shared savings or preliminary shared losses payments  Requirements: ESCOs must successfully report CEC measure set with satisfactory reporting for data quality measures  Attribution: Based on first dialysis utilization encounter with a participating facility; conducted quarterly  Volume: N/A  Risk stratification or adjustment: Organizations are categorized as either large dialysis organizations (LDOs; with 200+ dialysis facilities) and small dialysis organizations  Benchmarking: Based on historical Medicare Parts A and B expenditures for beneficiaries | Measures used for monitoring: Same as for implementation  How achievement is measured: Using a sliding scale, ESCO performance is ranked and points are awarded if being in the 30-99% percentile of national performance  How improvement is measured: The improvement scale connects the percentile of national performance, quality points earned, and the percentage change from the prior year |   |

 $<sup>^{\</sup>rm 35}$  ESCOs comprise nephrologists, dialysis facilities, and other providers.



| Program/<br>Model Name                                | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success                                 | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|---|---|---|--|--|---|
|   |   | readmission ratio,<br>standardized mortality<br>ratio, standardized first<br>kidney transplant waitlist<br>ratio for incident dialysis<br>patients, percentage of<br>prevalent patients<br>waitlisted   | who would have been aligned<br>to the ESCO in each of the<br>three years prior to the start of<br>the first PY, trended forward<br>using national data |  |   |
|   |   | Spending measure(s):<br>Total Medicare Parts A<br>and B spending  |  |  |   |
|   |   | Patient experience measure(s): In Center Hemodialysis; CAHPS (ICH CAHPS) score based on six sub-measures: nephrologists' communication and care, quality of dialysis center care and operations, providing information to patients, rating of kidney doctors, rating of dialysis center staff, and rating of dialysis Center; Kidney disease quality of life (KDQOL) survey |  |  |   |
| Comprehensive<br>Primary Care<br>Plus ( <u>CPC+</u> ) | Clinical Focus:<br>Primary care                                 | Utilization measure(s):<br>Emergency Department<br>Utilization, Acute Hospital<br>Utilization   | How payment is adjusted for performance: Practices receive performance-based incentive payments (PBIPs)  | Measures used for implementation: Emergency Department Utilization; Acute Hospital | At the start of<br>CPC+, PBIP<br>scores differed<br>markedly by         |



| Program/<br>Model Name                   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|--|--|---|--|---|---|
| No longer active Years active: 2017-2021 | Providers: Primary care providers (PCPs) Setting: Primary care practice Patient Population: All Medicare and Medicaid beneficiaries in participating regions | Quality measure(s): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%); and Controlling High Blood Pressure. Both quality measures are reported as electronic clinical quality measures (eCQMs).  Spending measure(s): Total Medicare Parts A and B spending  Patient experience measure(s): Patient Experience of Care Survey, measured by response to questions from the Consumer Assessment of Healthcare Providers and Systems Clinician and Group (CG-CAHPS) Survey and the Patient-Centered Medical Home Survey Supplement | based on patient experience, clinical quality, and utilization; practices retain all or a portion of the PBIP based on performance. The PBIP is paid prospectively for the entire subsequent year based on the prior year's performance. Practices that do not meet the annual performance thresholds for clinical quality/patient experience or utilization are "at risk" for repaying all or a portion of the PBIP.  Requirements: To retain quality and utilization components of the PBIP, CPC+ practices must:  -Report two eCQMs and receive a Patient Experience Survey score; practices failing to meet this requirement are not eligible to keep the quality or utilization component of the PBIP  -Meet the 30th percentile on 1 out of 3 quality measures; practices failing to meet this requirement are not eligible to keep the quality or utilization component of the PBIP | Utilization; Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%); Controlling High Blood Pressure; Medicare Parts A and B spending; Patient Experience of Care Survey Measures used for monitoring: Same as for implementation How achievement is measured: The PBIP retained is calculated by comparing a CPC+ practice's performance with benchmark thresholds derived using a reference population. CPC+ practices may set goals by comparing their performance with benchmark performance thresholds on measures of utilization, spending, and quality of care. How improvement is measured: Practices may use these benchmarks to track their performance over time. | practice ownership status, with independent practices outperforming system-owned practices, especially on utilization, but this performance gap narrowed steadily over time. By PY 4, the performance gap had largely disappeared, with system-owned practices attaining a median overall score of 95 percent, compared to 97 percent for independent practices. Some practices also noted that financial incentives were not always viewed as large enough to compensate for the effort required to participate in |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable  |
|------------------------|---|--|--|--|--|
|                        |   |  | -Meet the 30 <sup>th</sup> percentile on 2 out of 3 quality measures (utilization gate); practices failing to meet this requirement are not eligible to keep the utilization component of the PBIP, and the percent of the quality component retained is the combined dollar amount based on individual performance that meets or exceeds the 30 <sup>th</sup> percentile for the quality measures  -Meet the 70 <sup>th</sup> percentile on 2 out of 3 quality measures and meet the 30 <sup>th</sup> percentile on all 3 quality measures. For practices failing to meet this requirement, the percent of the quality component retained is the combined dollar amount based on individual performance that meets or exceeds the 30 <sup>th</sup> percentile for the quality measures and the percent of the utilization component retained is the combined dollar amount based on the individual performance for each of the 2 utilization measures. Practices that meet this requirement retain 100% of the quality component and the percent of |  | the model. Deep-dive practices noted that they deprioritized proactive outreach to patients about gaps in care and routine screenings because they had limited capacity to see patients in person. These practices reported that they expect their performance on quality metrics to suffer, especially for measures that require in-person measurements such as the controlling high blood pressure electronic Clinical Quality Measure (eCQM), which affects CPC+ practices' Performance-based Incentive Payment. Most deep-dive |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable  |
|------------------------|---|--|--|--|--|
|                        |   |  | the utilization component retained is the combined dollar amount based on the individual performance for each of the 2 utilization measures.   |  | practices reported<br>that episodic care<br>management was<br>useful in educating<br>patients about                    |
|                        |   |  | Attribution: Beneficiaries are prospectively attributed to CPC+ practice sites, rather than individual practitioners, under both voluntary alignment and claims-based attribution for each payment quarter.  |  | their health, providing practitioners and staff with detailed admission and discharge information, identifying gaps in |
|                        |   |  | Voluntary: Process by which beneficiaries specify the health care practitioner and practice that they consider to be responsible for providing and coordinating their health care. Attestations made by the end of the lookback period are used for attribution to pay practices prospectively (using historical data to perform attribution before each payment quarter). |  | care, and ultimately reducing readmissions.  |
|                        |   |  | Claims-based: Prospective, using a two-year "look back" period to identify eligible primary care visits (e.g., evaluation and management [E&M], welcome and annual wellness visits, advance care planning, collaborative care  |  |  |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|--|--|---|
|                        |   |  | model, cognition and functional assessment for patients with cognitive impairment, outpatient clinic visit for assessment and management (CAHs only), transitional care management (TCM), chronic care management (CCM), complex CCM, assessment/care planning for patients requiring CCM services, and care management services for behavioral health attribution) based on HCPCS codes. Beneficiaries are attributed to practices based on CCM-related services first, followed by annual wellness visits or welcome to Medicare visits, and then using the plurality of eligible primary care visits. |  |   |
|                        |   |  | Volume: At least 20 reporting practitioners or groups must meet the MIPS eligible clinician criteria for contributing to MIPS benchmarks for a benchmark to be created. These practitioners or groups must also each have a minimum case size of 20 beneficiaries.  Risk stratification or adjustment: All Medicare FFS  |  |   |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|---|--|---|
|                        |   |  | beneficiaries attributed to a CPC+ practice are assigned to one of four risk tiers for Track 1 or one of five risk tiers for Track 2. Risk score tier thresholds are defined separately for each CPC+ region. Each risk tier corresponds to a specific monthly CMF payment. Higher risk tiers are associated with higher beneficiary risk and higher CMFs. Beneficiary risk is generally determined by the CMS HCC risk adjustment model. For Track 2 beneficiaries, risk tier is also based in part on a diagnosis of dementia.  Benchmarking: The PBIP retained is calculated by comparing a CPC+ practice's performance with benchmark |  |   |
|                        |   |  | performance thresholds derived using a reference population. The benchmarks establish the minimum thresholds that CPC+ practices must reach to retain a portion of the incentive payment and the maximum thresholds that practices must achieve to retain the full incentive payment. Benchmarks are based on   |  |   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|--|--|--|--|---|
|  |  |  | quality (patient experience of care and clinical quality) and utilization (Medicare acute care utilization).   |  |   |
| Enhancing<br>Oncology<br>Model (EOM)<br>Ongoing<br>Years active:<br>2022-present | Clinical Focus: Oncology Providers: Oncologists Setting: Oncology practices Patient Population: Medicare beneficiaries with cancer | Utilization measure(s): Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy Quality measure(s): Proportion of Patients who Died who Were Admitted to Hospice for 3 Days or More; Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life; Pain Assessment and Management Set: a) Oncology: Medical and Radiation - Pain Intensity Quantified, b) Oncology: Medical and Radiation - Plan of Care for Pain; Preventative Care and Screening: Screening for Depression and a Follow- Up Plan | How payment is adjusted for performance: Retrospective performance-based payment (PBP) or performance-based recoupment (PBR) based on quality and savings during the performance period (i.e., 6-month episodes of care).  Requirements: Participants report participant-level quality measure data, beneficiary-level clinical and staging data, and beneficiary-level sociodemographic data to CMS no more than once a performance period. The PBP or PBR is calculated as a percentage of the benchmark amount for an attributed episode. An EOM Participant could earn a PBP if actual expenditures for attributed episodes are below the target amount.  Attribution: CMS attributes an episode to an eligible EOM Participant if the Participant | Measures used for implementation: All listed measures.  Measures used for monitoring: Not specified.  How achievement is measured: To calculate quality performance, CMS will compare participants' performances on each quality measure to the measure benchmark and calculate the participant's aggregate quality score (AQS). CMS will crosswalk the participant's AQS to the PBP or PBR performance multiplier to arrive at the payment amount.  How improvement is measured: Not specified. | N/A   |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|---|--|---|
|                        |   | Spending measure(s): Total cost of care  Patient experience measure(s): Patient- Reported Experience of Care Survey based on the Consumer Assessment of Healthcare Providers and Systems (CAHPS) for cancer drug therapy and other validated surveys to assess end-of-life and hospice care (e.g., CAHPS Hospice Survey) | provided the first qualifying E&M service during the episode if that Participant provided at least 25% of all qualifying E&M services for the episode.  Otherwise, CMS attributes the episode based on plurality of qualifying E&M services and the episode is attributed to the Participant providing the largest proportion of qualifying E&M services during the episode.  Volume: If a Participant does not have enough episodes to meet the minimum denominator for a measure, the measure is excluded from the calculation of the Aggregate Quality Score (AQS) for the performance period.  Risk stratification or adjustment: Cost benchmarks/target amounts are adjusted based on cancer type, dual eligible status and Low-Income Subsidy eligibility.  Benchmarking: The benchmark amount is the total projected costs of attributed episodes. CMS creates a separate price prediction model for each cancer type. After |  |   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population   | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable  |
|--|---|--|--|--|--|
|  |   |  | using these models to establish predicted expenditures for each EOM episode, CMS applies a series of adjustments to obtain the benchmark price for each episode.   |  |  |
| Treatment Choices (ETC) Model Ongoing Years active: 2021-present | Clinical Focus: Home dialysis and kidney transplants for patient with ESRD  Providers: Nephrologists  Setting: ESRD facilities, transplant centers, large donor hospitals, patient home  Patient Population: Patients with ESRD | Utilization measure(s): N/A  Quality measure(s): Home Dialysis Rate; Transplant Rate  Spending measure(s): Per treatment payments for dialysis  Patient experience measure(s): N/A | How payment is adjusted for performance: Participants receive a home dialysis payment adjustment (HDPA) and a performance payment adjustment (PPA). Medicare claim payments are increased for facilities and clinicians supporting dialysis at home and PPAs are either increased or decreased based on the rate of home dialysis and transplant rate, calculated as the sum of the transplant waitlist rate and the living donor transplant rate.  Requirements: All participants receive positive adjustments for home dialysis during the first three years of the model. The direction and magnitude of the PPA adjustment is determined based on the Modality Performance Score (MPS), which is assigned by CMS based on performance on the | Measures used for implementation: Home Dialysis Rate, Transplant Rate  Measures used for monitoring: Not specified How achievement is measured: CMS compares Participants' rates to the percentile-based benchmarks and assigns points using an achievement score scale ranging from 0 to 2 points. How improvement is measured: CMS calculates percent improvement as the difference between the model and base year rates divided by the base year rate, multiplied by 100. Points are assigned using an improvement score scale ranging from 0 to | Future model evaluations should account for possible effects of the related Kidney Care Choices (KCC) Model due to model overlap |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|--|---|---|
|                        |   |  | home dialysis rate and transplant rate.  Attribution: A beneficiary is attributed to the ESRD facility with the most dialysis claims during the month, and the Managing Clinician billing the first monthly capitated payment for the month. Attribution occurs on a month-by-month basis  Volume: N/A  Risk stratification or adjustment: Benchmarks are stratified by dual eligible or Low Income Subsidy (LIS) beneficiaries. Further, the transplant waitlist rate is risk-adjusted based on beneficiary age  Benchmarking: Achievement – CMS calculates benchmark year home dialysis rate and transplant rate and then calculates the 30th, 50th, 75th, and 90th percentiles of the distributions. Improvement – CMS assesses the home dialysis rate and transplant rate against the base year rates to calculate an improvement score. | 1.5. Participants are evaluated according to whether their percent improvement falls within >10%, >5%, >0%, and 0 or <0% improvement. Further, there is a Health Equity Incentive to the improvement scoring methodology: participants who show improvement in the home dialysis rate or transplant rate for their attributed dual-eligible or Low Income Subsidy (LIS) beneficiaries can earn additional improvement points. |   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population   | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|---|---|---|--|---|
| Expanded Home Health Value-Based Purchasing Model (Expanded HHVBP) Ongoing Years active: January 2022- present | Clinical Focus: Home health care  Providers: Medicare- certified Home Health Agencies (HHAs)  Setting: Home health setting  Patient Population: Medicare beneficiaries requiring home health services | Utilization measure(s): Acute Care Hospitalization During the First 60 Days of Home Health Use; ED Use without Hospitalization During the First 60 Days of Home Health/ED Use  Quality measure(s): Improvement in Dyspnea; Discharged to Community; Improvement in Management of Oral Medications; Total Normalized Composite Change in Self-Care; Total Normalized Composite Change in Mobility  Spending measure(s): Home health Medicare claims payments  Patient experience measure(s): HHCAHPS Care of Patients/Professional Care; Communication between Providers and Patients; Specific Care Issues/Team Discussion; Overall Rating of Home Health Care; Willingness | How payment is adjusted for performance: Home health agencies receive adjustments to their FFS payments based on their Total Performance Score (TPS), a composite score of an agency's quality measures, relative to peers' performance. Performance on quality measures impacts payment adjustments in a later year.  Requirements: CMS will apply a payment adjustment of a maximum of 5% upward or downward in the performance year based on an HHAs performance in the baseline year. When calculating the TPS, quality and utilization measures are weighted 35% and patient experience measures are weighted 30%.  Attribution: N/A  Volume: To qualify for payment adjustments, an HHA must have 20 home health quality episodes, 20 home health stays, and 40 completed HHCAHPS surveys, along with sufficient data to calculate at | Measures used for implementation: All listed measures  Measures used for monitoring: Same as for implementation  How achievement is measured: TPS compared to the achievement threshold, which is the 50th percentile of all HHAs' performance scores for that quality measure within the cohort during the baseline year, with achievement points being assigned for values that are greater than the threshold  How improvement is measured: Measure values are compared to the improvement threshold, with achievement points being assigned for values that are greater than the threshold | N/A (Model has not been evaluated yet)                                  |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population               | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|---|--|---|--|---|
|  |   | to Recommend the Agency  | least five of the 12 quality measures in the baseline and performance years  Risk stratification or adjustment: Cohorts are determined by the HHAs beneficiary count in the prior calendar year: large-volume (HHAs with 60+ beneficiaries in the calendar year prior to the performance year) or small-volume (HHAs with <60 beneficiaries); cohorts group HHAs of similar size and likelihood to receive scores on the same set of measures  Benchmarking: Achievement thresholds and benchmarks are calculated as the 50th and 90th percentiles for each quality measure by cohort, based on all HHAs' performance data in the designated baseline year. |  |   |
| Accountable Care Organization Realizing Equity, Access, and Community Health | Clinical Focus: Primary and specialty care Providers: ACOs; Participating and | Utilization measure(s): N/A  Quality measure(s): Days at home for patients with complex, chronic Conditions (for high-needs DCEs only); timely follow-up (TFU) after acute | How payment is adjusted for performance: CMS calculates the total cost of care at the end of the performance year. If the payments and additional FFS Medicare expenditures exceed the performance year benchmark, the ACO repays   | Measures used for implementation: Initial quality score (IQS), a percentage determined by the four quality measures (ACR, UAMCC, TFU, CAHPS) out of a total of 40 points | Not specified   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population   | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|---|--|--|---|---|
| (ACO REACH)  Participants  Announced  Years active: 2021-present <sup>36</sup> | Preferred Providers  Setting: Broad applicability  Patient Population: Medicare FFS beneficiaries; patients with complex chronic diseases and serious illnesses | exacerbations of chronic conditions (for Standard and New Entrant DCEs only); risk-standardized all condition readmission (ACR) measure; all-cause unplanned admissions for patients with multiple chronic conditions (UAMCC)  Spending measure(s): Total cost of care  Patient experience measures from CAHPS, patient/caregiver experience | CMS the shared losses according to its risk sharing arrangement; otherwise, CMS pays shared savings to the ACO. Advanced Payment Option (APO) payments are also reconciled in a similar manner.  Requirements: To earn shared savings, participants must exceed the benchmark.  Attribution: Prospective voluntary; Prospective Plus voluntary; Prospective, claims-based, primary care providers; Prospective, claims-based, non-primary care <sup>37</sup> Volume: N/A  Risk stratification or adjustment: Participants are organized into three types: Standard ACOs, New Entrant ACOs, and High Needs ACOs. Risk adjustment is used to adjust expenditures for beneficiary health risk and | Measures used for monitoring: Same as for implementation  How achievement is measured: Performance on each of the four quality measures (ACR, UAMCC, TFU, CAHPS) on a scale of 10 compared to the relevant benchmark  How improvement is measured: CMS determines whether REACH ACOs exhibit improvement, no change, or a decline in performance on measure scores for each quality measure |   |

<sup>&</sup>lt;sup>36</sup> The transition from the GPDC Model to the ACO REACH Model was announced on February 24, 2022. The ACO REACH Model began on January 1, 2023.

Final | March 2024

<sup>&</sup>lt;sup>37</sup> For additional details on attribution, refer to *Environmental Scan on Improving Management of Care Transitions in Population-Based Models*, available at <a href="https://aspe.hhs.gov/sites/default/files/documents/61e603e1beb3f5eb4d528b1e91fadf12/PTAC-Jun-12-Escan.pdf">https://aspe.hhs.gov/sites/default/files/documents/61e603e1beb3f5eb4d528b1e91fadf12/PTAC-Jun-12-Escan.pdf</a>.



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|--|--|--|---|---|---|
|  |  |  | establish performance year benchmarks.  Benchmarking: Based on historical baseline expenditures and/or KSS rate book or a blend of historical and regional expenditures or regional expenditures, depending on ACO type and alignment   |   |   |
| Home Health<br>Value-Based<br>Purchasing<br>(HHVBP) Model<br>No Longer<br>Active<br>Years active:<br>2016-2021 | Clinical Focus: Home health care  Providers: Medicare- certified Home Health Agencies (HHA)  Setting: Home health setting  Patient Population: Medicare beneficiaries requiring home health services | Utilization measure(s): Acute care hospitalization during the first 60 days of home health; ED use without hospitalization during the first 60 days of home health  Quality measure(s): Discharge to community; total normalized composite change in self-care; total normalized composite change in mobility; improvement in management of oral medications; improvement in dyspnea | How payment is adjusted for performance: Medicare payments were adjusted upward or downward by up to 3%, 5%, 6%, or 7% based on the Total Performance Score, a composite score of an agency's quality achievement/improvement on the measure set and the performance year.  Requirements: Payment adjustments were based on prior TPS (I.e., adjustments began in CY 2018 based on 2016 TPS for up to +/- 3% while CY 2021 is based on 2019 TPS for up to +/- 7%)  Attribution: N/A <sup>38</sup> | Measures used for implementation: Total Performance Score Measures used for monitoring: Same as for implementation How achievement is measured: Total performance score compared against the benchmark How improvement is measured: Percent relative change among total performance score and total normalized composite scores | An evaluation report found that the model had performance gaps among agencies within individual states or regions that may have implications for health equity. A larger gap between patients with and without Medicaid emerged over time in HHVBP states compared with non-HHVBP states, which translated to a |

 $<sup>^{38}</sup>$  All Medicare-certified HHAs from participating states are included in the HHVBP Model.

Final | March 2024



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|--|--|---|--|--|---|
|  |  | Spending measure(s): Home health Medicare claims payments  Patient experience measure(s): Patient experience measures from CAHPS surveys  | Volume: N/A Risk stratification or adjustment: N/A Benchmarking: Achievement thresholds are based on the median measure value for all HHAs in the state during the baseline period. Benchmarks are based on the mean measure value for the best performing decile of all HHAs in the state during the baseline period. |  | slightly larger widening in the disparity over time in HHVBP states. evidence of persisting quality gaps based on Medicaid status as well as race and ethnicity under the original HHVBP Model suggests a need for more targeted initiatives to reduce these pre-existing inequities among home health patients and to align with CMS' Framework for Health Equity. |
| Independence<br>at Home (IAH)<br>Demonstration<br>Ongoing<br>Years Active:<br>2011-present | Clinical Focus: Primary care, chronically ill  Providers: Primary care providers  Setting: Home- based | Utilization measure(s): Hospital admissions for ambulatory care sensitive conditions; ED visits for ambulatory care sensitive conditions  Quality measure(s): Follow-up contact within 48 hours of a hospital | How payment is adjusted for performance: Practices can receive 50% of shared savings for meeting/exceeding performance requirements on three measures, 66.7% of shared savings for four measures, 83.3% for five   | Measures used for implementation: All listed measures  Measures used for monitoring: All listed measures  How achievement is measured: CMS compares practices' | Few practices met<br>the threshold for<br>the 48-hour follow-<br>up visit measure.<br>This could be due<br>to a variety of<br>factors, such as<br>whether the<br>practice receives<br>timely notification   |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population             | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|------------------------|---|---|---|--|---|
|                        | Patient Population: Medicare beneficiaries with multiple chronic conditions | admission, hospital discharge, or  ED visit; Medication reconciliation in the home within 48 hours of a hospital discharge or ED visit; Annual documentation of patient preferences; All-cause hospital readmissions within 30 days  Spending measure(s): Medicare Part A and Part B FFS expenditures  Patient experience measure(s): N/A | measures, and 100% for all six measures.  Requirements: Practices actual expenditures must be at least 5% below the target and they must meet or exceed performance requirements on at least three of the six quality measures to share in savings through an incentive payment.  Attribution: N/A  Volume: Must serve at least 200 eligible beneficiaries  Risk stratification or adjustment: Benchmarks are adjusted to reflect the average Hierarchical Condition Category (HCC) risk score, the average frailty score, and a utilization factor for the IAH population in each practice.  Benchmarking: Use a revised actuarial methodology that generates practice-specific per beneficiary per month (PBPM) target expenditures based on historical Medicare FFS per capita expenditures for the Medicare FFS population in the same counties as IAH beneficiaries. | performance for each quality measure against the thresholds  How improvement is measured: CMS compares practices' performance on quality measures across years | of a beneficiary having a hospital admission or ED visit and whether the practice had clinicians who made after-hours and weekend visits. |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|--|--|--|---|---|---|
| Kidney Care Choices (KCC) Model Ongoing Years active: 2020-present | Clinical Focus: ESRD Providers: Accountable care/dialysis facilities, nephrologists, and other health care providers form ESRD-focused ACOs (Kidney Contracting Entities <sup>39</sup> [KCEs]) Setting: Dialysis facilities Patient Population: Patients with ESRD | Utilization measure(s): N/A  Quality measure(s): Gains in Patient Activation Scores at 12 Months; Depression Remission at 12 Months; Optimal ESRD Starts  Spending measure(s): CKD Cost of Care; ESRD Cost of Care  Patient experience measure(s): N/A | How payment is adjusted for performance: Kidney Care First (KCF) Option – adjusted capitated payments for managing care of aligned beneficiaries and for those on dialysis based on health outcomes and utilization relative to both the participants' own experience and national standards, and performance on quality measures. KCF Practices can also receive bonus payments for successful kidney transplants; Comprehensive Kidney Care Contracting (CKCC) Graduated, Professional and Global Options – Kidney Contracting Entities (KCEs) receive adjusted capitation payments and can receive a portion or all of the Medicare savings they achieve based on their total cost of care compared to the benchmark as well as their performance on a set of quality measures. CKCC | Measures used for implementation: relative performance on quality and cost measures  Measures used for monitoring: Relative and continuous improvement performance on quality and cost measures  How achievement is measured: KCEs are subject to quality withholds; KCEs earn back the withhold based on their quality score (compared to a relevant benchmark). KCEs that achieve a 100% quality score earn back the full quality withhold.  How improvement is measured: Continuous improvement performance on cost and utilization measures is defined when KCE participants outperform their own past performance. | N/A (Model has<br>not been<br>evaluated yet)                            |

<sup>39</sup> Nephrology practices and their nephrologists and nephrology professionals who meet certain eligibility requirements can participate in the Kidney Care First (KCF) Option. KCEs can participate in any of the Comprehensive Kidney Care Contracting (CKCC) Options and are required to include nephrologists or nephrology practices and transplant providers; optional participants in KCEs include dialysis facilities and other suppliers and providers.

Final | March 2024



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|--|---|--|---|
|                        |   |  | Graduated Option is a one-<br>sided risk track; CKCC<br>Professional Option provides<br>an opportunity to earn 50% of<br>shared saving or be liable for<br>50% of shared losses; CKCC<br>Global Option participants are<br>eligible to share in 100% of<br>earnings or losses.      |  |   |
|                        |   |  | Requirements: Transplant<br>bonuses are contingent on<br>success; Level 1 KCEs are<br>subject to a minimum savings<br>rate determined by the volume<br>of beneficiaries needed for<br>statistical confidence.   |  |   |
|                        |   |  | Attribution: Alignment based on where beneficiary receives the majority of their kidney care. When an aligned beneficiary receives a kidney transplant, they will remain aligned to participant for the following three years (if successful; otherwise, they could be re-aligned). |  |   |
|                        |   |  | Volume: KCF Practices must<br>have a minimum of 350 aligned<br>Medicare beneficiaries with<br>CKD Stages 4 or 5 and 200<br>aligned ESRD beneficiaries.<br>For the CKCC Model Options,   |  |   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population              | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable                             |
|--|--|---|--|--|---|
|  |  |   | KCEs must have a minimum of 750 beneficiaries with CKD Stages 4 or 5 and 350 ESRD beneficiaries.   |  |   |
|  |  |   | Risk stratification or adjustment:   |  |   |
|  |  |   | The KCF Option does not risk adjust. The CKCC Options use the CMS-HCC prospective risk adjustment model for beneficiaries with late-stage CKD and the CMS-HCC ESRD risk adjustment model for beneficiaries with ESRD to establish benchmarks. For KCEs, a KCE-level symmetric cap on risk score growth is applied. |  |   |
|  |  |   | Benchmarking: Based on historical baseline expenditures, prospectively trended forward each performance year (PY) using the projected U.S. per capita cost (USPCC).  |  |   |
| Making Care<br>Primary (MCP)<br>Model<br>Accepting<br>Applications | Clinical Focus: Primary care Providers: PCPs Setting: Primary care practices | Utilization measure(s): Emergency Department Utilization Quality measure(s): Controlling High Blood | How payment is adjusted for performance: Participants are eligible to receive upside-only Performance Incentive Payments (PIP) that reward participants for improving  | Measures used for implementation: TPCC Continuous Improvement (CI) measure for non-FQHCs and non-Indian Health Programs; | Given the length<br>of the model (10.5<br>years), CMS may<br>update the<br>measure set in<br>future |



| Program/<br>Model Name                     | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population         | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable                           |
|--|---|---|--|--|---|
| Years active:<br>Launching in<br>July 2024 | Patient Population: All Medicare beneficiaries in participating regions | Pressure; Diabetes Hba1C Poor Control; Colorectal Cancer Screening; Screening for Depression and Follow Up; Depression Remission within 12 months; Screening for Social Drivers of Health  Spending measure(s): Total Per Capita Cost (TPCC), reported as an observed-to-expected ratio for each participant, dividing the observed cost by the expected cost  Patient experience measure(s): Person- Centered Primary Care Measure (PCPCM) | patient health outcomes and achieving savings.  Requirements: Participants must report all quality measures for their Track (Tracks 1, 2, and 3) to receive a PIP adjustment. Once in Tracks 2 and 3, participants must meet or exceed the 30th percentile nationally for TPCC.  Attribution: Eligible beneficiaries are prospectively attributed to a participant.  Attribution is first determined by CMS based on the beneficiary's chosen alignment to a clinician. Otherwise, CMS will attribute the beneficiary to the participant if one or more of the participant's eligible clinicians provided the plurality of the beneficiary's primary care visits and/or eligible Chronic Care Management (CCM) services, or if one of the participant's eligible the beneficiary's most recent claim for an Annual Wellness Visit or a Welcome to Medicare Visit during the most recently available 24-month period. | Emergency Department Utilization CI for FQHCs and Indian Health Programs as well as the quality and patient experience measures listed.  Measures used for monitoring: CMS will use self-reported participants care delivery and financial information, MCP Clinician Lists, Specialty Care Partner Lists, claims, utilization, and quality data in its monitoring strategy. This information is collected through annual participant reporting.  How achievement is measured: Scoring and benchmarking structure allows participants to achieve tiered levels of success by providing stepped incentives via lower and upper thresholds for receipt of PIPs. Lower thresholds (to receive partial credit) and upper thresholds (to receive full credit) are set | performance years as new and innovative ways to measure quality and performance become available. |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|--|--|---|---|--|---|
|  |  |   | Volume: N/A Risk stratification or adjustment: Some measures within the MCP performance measure set are risk-adjusted; however, the model does not employ additional adjustments to inform the PIP. Benchmarking: Continuous Improvement Measures assess performance against participants' own historical performance; Other measures use regional or national benchmarks   | for the clinical quality, cost, and utilization measures.  How improvement is measured: Measures of participant-level CI carry significant weight in the PIP for Tracks 2 and 3. For the TPCC CI measure, participants are measured against their own TPCC performance in the previous year.         |   |
| Next Generation Accountable Care Organization (NGACO) No Longer Active Years active: 2016-2021 | Clinical Focus: Primary and specialty care Providers: Participating PCPs and specialists Setting: Primary and specialty care practices, hospitals, inpatient and outpatient settings | Utilization measure(s): N/A  Quality measure(s): Risk Standardized, All Condition Readmissions; Risk-Standardized Acute Admission Rates for Patients with Multiple Chronic Conditions; Days at Home  Spending measure(s): Total Medicare Parts A and B spending  Patient experience measure(s): CAHPS | How payment is adjusted for performance: The benchmarking methodology rewards NGACOs for favorable financial performance on spending relative to historical or regional benchmarks. NGACOs participate in shared savings or losses based on performance year expenditures. NGACOs may receive an Earned Quality Bonus for meeting quality requirements. CMS uses a quality "withhold," in which a portion of an ACO's | Measures used for implementation: The quality score is based on three measures: hospitalizations for ambulatory care sensitive conditions (ACSCs), 30-day hospital readmissions, and 30-day hospital readmissions from a SNF.  Measures used for monitoring: Quality and patient experience measures | An EHR meaningful use measure was dropped from the model: it was expected that ACOs who were ready and able to take on high levels of risk under the NGACO Model were already using Electronic Health Records (EHR) and already |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|---|--|---|---|
|                        | Patient Population: Original Medicare FFS beneficiaries         | measures, including Getting Timely Care, Appointments, and Information; How Well Your Doctors Communicate; Patients' Rating of Doctor; Access to Specialists; Health Promotion and Education; Shared Decision Making; Health Status/Functional Status; Stewardship of Patient Resources; Courteous and Helpful Office Staff | performance year benchmark is held "at-risk," contingent upon the ACO's quality score. An ACO that achieves a 100% quality score (a function of the ACO meeting quality measure benchmarks and reporting requirements) will have the full withhold re attributed to its performance year benchmark at settlement, while an ACO that achieves less than a 100% quality score will have a proportionate amount discounted from the withhold and re-attributed to its performance year benchmark.  Requirements: NGACOs must meet minimum quality requirements to participate in shared savings and the Earned Quality Bonus. If an NGACO does not meet the minimum requirements, they are still required to pay losses.  Attribution:  Voluntary: Beneficiaries confirm care relationships with participating providers (annual).  Prospective, claims-based: Beneficiaries are aligned to the | How achievement is measured: CMS utilized quality scores and measured spending against a benchmark based on historical and regional trends.  How improvement is measured: The Model offers financial arrangements with higher levels of risk and reward, using refined benchmarking methods that reward both attainment of and improvement in cost containment. | had robust systems in place.  |



| Program/<br>Model Name                              | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population       | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable                         |
|---|---|---|--|---|---|
|   |   |   | participating provider that provided the majority of that beneficiary's evaluation and management (E&M) visits (annual).   |   |   |
|   |   |   | Volume: N/A  Risk stratification or adjustment: Risk scores are used to adjust PY benchmarks, accounting for health status differences between beneficiaries from the baseline period and performance period. The discount that is applied to risk-adjusted baselines is dependent on whether the ACO selects a full or partial risk arrangement. Changes were made to the risk adjustment methodology as a result of COVID-19.  Benchmarking: Yes, prospectively set based on historical expenditures and national trends |   |   |
| Oncology Care<br>Model (OCM)<br>No Longer<br>Active | Clinical Focus:<br>Cancer care<br>Providers:<br>Oncology<br>providers | Utilization measure(s): N/A  Quality measure(s): Screening for Depression and Follow-up Plan; | How payment is adjusted for performance: The amount of the performance-based payment is adjusted based on the participant's achievement on a range of quality measures.  | Measures used for implementation: Risk-adjusted proportion of patients with all-cause hospital admissions within the 6-month episode; Risk- | Some practices raised concerns related to the lack of specificity in the validated measures for |



| Program/<br>Model Name  | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable  |
|-------------------------|---|--|---|---|--|
| Years active: 2016-2022 | Setting: Outpatient Patient Population: Patients with cancer    | Oncology: Medical and Radiation – Plan of Care for Pain; Oncology: Medical and Radiation – Pain Intensity Quantified; Proportion of Patients who Died who Were Admitted to Hospice for 3 Days or More; Risk-adjusted Proportion of Patients with All-Cause ED Visits or Observation Stays that did not Result in a Hospital Admission within the 6-month Episode; Risk-adjusted proportion of patients with all-cause hospital admissions within the 6-month episode; Closing the Referral Loop: Receipt of Specialist Report; Documentation of Current Medications in the Medical Record; Prostate Cancer: Adjuvant Hormonal Therapy for High or Very High Risk Prostate Cancer; Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under | OCM quality measure data derived from claims, aggregate measure results reported to the OCM Data Registry, and patient experience survey data, are utilized to determine the quality score used in calculation of the performance multiplier. Scoring, or the process of assigning quality points to each quality measure, is based on the OCM Participants' reporting of quality measure data and/or quality performance relative to set thresholds. Once quality points are assigned, an Aggregate Quality Score (AQS) will be calculated and translated into a performance multiplier. This performance multiplier is used as part of the performance-based payment calculation.  Requirements: To be eligible for performance period must have a target amount that exceeds actual episode expenditures of the episodes attributed to the practice. The practice or pool will also need | adjusted proportion of patients with all-cause emergency department visits or observation stays that did not result in a hospital admission within the 6-month episode; Proportion of patients who died who were admitted to hospice for 3 days or more; Care Plan; Closing the Referral Loop: Receipt of Specialist Report; Pain Assessment and Management Composite; Preventive Care and Screening: Screening for Depression and Follow-Up Plan; Patient-Reported Experience of Care; Prostate Cancer: Adjuvant Hormonal Therapy for High or Very High Risk Prostate Cancer; Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer; Combination chemotherapy is | depression. Further, practices with multiple EHRs across clinics/sites reported difficulty reporting quality measures at the practice level. |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement  | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|------------------------|---|---|--|---|---|
|                        |   | the age of 80 with AJCC III (lymph node positive) colon cancer; Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer; Trastuzumab administered to patients with AJCC stage I (T1c) - III and human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy; Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer  Spending measure(s):  All Medicare Part A and Part B expenditures, certain Part D expenditures | to meet or exceed an AQS minimum threshold of 30%. Further, the practice or pool must report aggregate measure results for practice-reported measures, and implement all Practice Redesign Activities to receive a PBP.  Attribution: Each episode is attributed to an individual practice. Visits are credited to the TIN or OCM ID (for OCM practices) with the majority of the beneficiary's cancer-related E&M visits during the 6-month episode. For pooled participants, episodes are still attributed to individual practices within the pool.  Volume: N/A; performance-based payments will be made only for higher-volume cancer types for which it is possible to calculate accurate benchmarks. Benchmarks will not be calculated for lower-volume cancer types.  Risk stratification or adjustment: Benchmark prices are risk-adjusted for factors that affect episodic expenditures and that are available in | recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer; Trastuzumab administered to patients with AJCC stage I (T1c) - III and human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy; Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer; Documentation of Current Medications in the Medical Record  Measures used for monitoring: Shared Decision Making composite measure; claims data and practice-reported quality measure and clinical data. |   |



| Program/<br>odel Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement               | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success   | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable |
|-----------------------|---|--|---|--|---|
|                       |   | Patient experience measure(s): Patient-Reported Experience of Care | Medicare claims data, including age, sex, dual eligibility for Medicaid and Medicare, selected non-cancer comorbidities, receipt of selected cancer-directed surgeries, receipt of bone marrow transplant, receipt of radiation therapy, type of chemotherapy drugs used during episode (for breast, prostate, and bladder cancers only), institutional status, participation in a clinical trial, history of prior chemotherapy use, episode length, and hospital referral region. The risk-adjusted ED visit and observation stay measure is risk-adjusted using a hierarchical logistic regression model that incorporates many of the same risk adjustment variables used in setting episode spending benchmarks, including cancer type, demographics, institutional status, geographic location, and comorbidities.  Benchmarking: CMS calculates benchmark episode expenditures for OCM practices | How achievement is measured: Practices earn quality points that contribute to an Aggregate Quality Score (AQS) to measure performance. Practice-reported expenditure and quality measures are compared against thresholds.  How improvement is measured: N/A |   |



| Program/<br>Model Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement   | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable   |
|--|--|--|--|---|---|
|  |  |  | based on historical data. Benchmarks are adjusted for risk (e.g., patient sociodemographics, clinical characteristics) and geographic variation, trended to the applicable performance period, and include a novel therapies adjustment. A discount is applied to the benchmark to determine a target price for OCM-FFS episodes. Pay-for-performance measures are assigned quality points based on the practice's or pool's performance as compared to set thresholds, called quality benchmarks. |   |   |
| Primary Care<br>First (PCF)<br>Model Options<br>Ongoing<br>Years active:<br>2021-present | Clinical Focus: Primary care Providers: PCPs Setting: Primary care practices Patient Population: Medicare patients with serious illness/chronic conditions | Utilization measure(s): Acute hospital utilization (the overall observed-to- expected ratio of acute inpatient and observation stay discharges)  Quality measure(s): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%); Controlling High Blood Pressure; Colorectal Cancer Screening; Advance Care Plan | How payment is adjusted for performance: A practice's payment amount depends on its performance compared to peer practices and its degree of improvement compared to its historical performance.  Performance-based payment can be up to a 50% increase or a 10% decrease in total primary care payment revenue.  Requirements: To be eligible for a performance-based   | Measures used for implementation: Acute hospital utilization, HbA1c poor control, controlling high blood pressure, colorectal cancer screening, advance care plan, total per capita cost, and CAHPS  Measures used for monitoring: Same as for implementation | Among the 13 PCF participants assessed in the first evaluation report, only 5 of the 13 payer partners offered financial incentives tied to outcome measures, using cost and utilization metrics. Several practices |



| Program/<br>Model Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance<br>Measurement   | Technical Issues Related to<br>Performance Measurement  | How Measurement is<br>Used to Determine<br>Success  | Gaps Related to<br>Current<br>Performance<br>Measures, as<br>applicable                       |
|------------------------|---|--|---|---|---|
|                        |   | Spending measure(s): Total per capita cost  Patient experience measure(s): Patient Experience of Care Survey (Consumer Assessment of Healthcare Providers and Systems [CAHPS]) | payment, practices must meet minimum performance thresholds for quality measures and their practice performance must be above 50th percentile of the National Benchmark. Performance thresholds and measures vary by risk group.  Attribution: CMS identifies eligible beneficiaries using Medicare administrative data and conducts voluntary alignment. CMS also uses a claims-based attribution approach to identify other eligible beneficiaries.  Volume: N/A  Risk stratification or adjustment: CMS assigns practices to 4 risk groups using average CMS-HCC risk scores of their attributed beneficiaries.  Benchmarking: Benchmarks are based on the 30th percentile and use either the 2022 MIPS benchmark population or a CMS-derived 2021 national benchmark population for performance year 2023 | How achievement is measured: The practice's utilization measure (for risk groups 1 and 2) or spending measure (for risk groups 3 and 4) performance is compared to that of its peer region group, leading to a rating of 1-7 that corresponds to its performance-based payment percentage adjustment. To pass the Quality Gateway, risk group 1 and 2 practices must exceed the 30th percentile for all quality and patient experience measures. Risk group 3 and 4 practices must exceed the 30th percentile for the advance care plan and CAHPS measures to pass the Quality Gateway. How improvement is measured: Practices can also receive an improvement bonus for improving their performance over time (percent improvement). | expressed concerns about the timeliness and quality of beneficiary data provided through PCF. |



#### Exhibit C2. Lessons Learned

| Program/Model<br>Name   | Clinical Focus, Providers,<br>Setting, Patient Population  | Lessons Learned Related to Performance<br>Measurement  |
|---|--|--|
| Bundled Payments for Care Improvement Advanced (BPCI-A) Ongoing Years active: 2018- Present | Clinical Focus: Cross- clinical focus  Providers: Acute care hospitals, physician group practices, Medicare-enrolled providers  Setting: Inpatient and outpatient services  Patient Population: Medicare beneficiaries with certain clinical episodes (29 inpatient, 3 outpatient) | The model reduced total episode payments, institutional post-acute care (PAC) payments, discharges to institutional PAC settings, and the number of skilled nursing facility (SNF) days among patients who received SNF care relative to the comparison group.   |
| Comprehensive<br>ESRD Care (CEC)<br>Model<br>No longer active<br>Years active:<br>2015-2021 | Clinical Focus: End-stage renal disease (ESRD)  Providers: Nephrologists; ESRD Seamless Care Organizations (ESCOs) <sup>40</sup> Setting: Nephrology clinics  Patient Population: Medicare beneficiaries with ESRD   | An evaluation after performance year 5 (evaluation through December 31, 2020) <sup>41</sup> found there was a 3% decrease in the number of hospitalizations and a 0.4% increase in the number of outpatient dialysis sessions. Additionally, CEC beneficiaries experienced 5% fewer hospitalizations from ESRD complications and were 5% less likely to use a catheter compared to non-CEC beneficiaries. The Model also improved phosphate binder adherence by 9%. From PY1-PY5, the model reduced Medicare spending by \$217 million (1.3%) prior to shared savings payments, however most of this was attributed to Wave 1 ESCOs. |

 $^{\rm 40}$  ESCOs comprise nephrologists, dialysis facilities, and other providers.

Final | March 2024

٠

<sup>41</sup> https://www.cms.gov/priorities/innovation/data-and-reports/2022/cec-annrpt-py5-fg



| Program/Model<br>Name   | Clinical Focus, Providers,<br>Setting, Patient Population   | Lessons Learned Related to Performance<br>Measurement   |
|---|---|---|
| Comprehensive Primary Care Plus (CPC+) No longer active Years active: 2017-2021 | Clinical Focus: Primary care Providers: Primary care providers (PCPs) Setting: Primary care practice Patient Population: All Medicare and Medicaid beneficiaries in participating regions | The fourth annual report <sup>42</sup> found a reduction in acute care utilization and improvement in some quality-of-care measures over the first four years of implementation. However, CPC+ did not reduce Medicare expenditures without enhanced payments; expenditures including enhanced payments increased by 1.5% in Track 1 and 2.6% in Track 2. There was a 1.5% reduction in total Medicare expenditures in PY4 for Track 1 Shared Savings Program practices. Although 95% of practices reported an improvement in care quality, there was little evidence that CPC+ improved continuity, fragmentation, comprehensiveness of care, 30-day unplanned readmissions, or mortality; average rates of emergency department (ED) and hospital follow-up increased from 2017 to 2019. CPC+ practices engaged in transformation activities to improve quality of care. Transformation activities may be in domains of access and continuity (e.g., 24/7 patient access), care management (e.g., care plans for high-risk chronic disease patients), comprehensive and coordinated care (e.g., behavioral health integration), patient and caregiver engagement (e.g., convening a patient and family advisory council), and data-driven population health management (e.g., weekly care team review of population health data). Other contextual factors, such as SDOH and patient preferences, could limit the degree that patients engage with improved primary care and therefore alter their behavior and outcomes. |
| Enhancing Oncology Model (EOM) Ongoing Years active: 2022-present               | Clinical Focus: Oncology Providers: Oncologists Setting: Oncology practices Patient Population: Medicare beneficiaries with cancer  | EOM builds on lessons learned from the Oncology Care Model (OCM) and shares certain features with the OCM, including a similar quality measure set. The EOM model performance period began in July 2023. Model evaluations have not been completed yet. Thus, there are no lessons learned related to performance measurement.  |

<sup>42</sup> Independent Evaluation of Comprehensive Primary Care Plus: Fourth Annual Report (cms.gov)



| Program/Model<br>Name   | Clinical Focus, Providers,<br>Setting, Patient Population   | Lessons Learned Related to Performance<br>Measurement   |
|---|---|---|
| ESRD Treatment<br>Choices (ETC)<br>Model<br>Ongoing<br>Years active:<br>2021-present                            | Clinical Focus: Home dialysis and kidney transplants for patient with ESRD  Providers: Nephrologists  Setting: ESRD facilities, transplant centers, large donor hospitals, patient home  Patient Population: Patients with ESRD | Year 2 results <sup>43</sup> showed 66% of ESRD facilities and 78% of managing clinicians had higher home dialysis rates, and 48% of facilities and 51% of managing clinicians had higher transplant rates than the respective benchmarks (defined as the 50th percentile). Additionally, 80% of facilities and 70% of managing clinicians improved their home dialysis rate and 61% of facilities and 62% of managing clinicians improved their transplant rates from benchmark year 2 (January 1, 2020 – December 31, 2020) to measurement year (July 1, 2021 – June 30, 2022). Approximately half of ESRD facilities (46%) and managing clinicians (54%) received a positive performance payment adjustment. |
| Expanded Home Health Value- Based Purchasing Model (Expanded HHVBP) Ongoing Years active: January 2022- present | Clinical Focus: Home health care  Providers: Medicarecertified Home Health Agencies (HHAs)  Setting: Home health setting  Patient Population: Medicare beneficiaries requiring home health services                             | Model evaluations have not been completed yet.  |

 $<sup>^{43}\</sup> https://www.cms.gov/priorities/innovation/media/document/etc-my2-aag$ 



### Program/Model Name

### Clinical Focus, Providers, Setting, Patient Population

#### Lessons Learned Related to Performance Measurement

Global and
Professional
Direct
Contracting
(GPDC)/Account
able Care
Organization
Realizing Equity,
Access, and
Community
Health (ACO
REACH)

Participants Announced

Years active: 2021-present<sup>44</sup>

**Clinical Focus:** Primary and specialty care

**Providers:** Direct Contracting Entities (DCEs) under GPDC, ACOs under ACO REACH; Participating and Preferred Providers

Setting: Broad applicability

Patient Population: Medicare FFS beneficiaries; patients with complex chronic diseases and serious illnesses A summary of GPDC model performance of the first performance year and first three guarters of the second PY<sup>45</sup>, last updated April 2023, compared all-condition readmissions (ACR) and unplanned admissions for patients with multiple chronic conditions (UAMCC) per 100 beneficiaries with multiple chronic conditions per year. The UAMCC score showed GPDC Model participants performed better than practices who did not participate in the model (30.65 versus 32.54), but the ACR scores among participants and non-participants were similar (15.21% versus 15.18%). The total dollars under risk (the sum of the performance year benchmark across the 99 PY2022 DCEs) was consistent with the average perbeneficiary-per-month benchmark of approximately \$1,117. Across the 99 DCEs that participated in PY2022, they saw roughly a 1.6% reduction in Medicare spending compared to their combined benchmarks in PY2022.

As of the first evaluation report, DCEs' most highly prioritized strategies for population health management focused on avoidable utilization (90%), complex or population-specific care management (90%), and investments in primary care (63%). While there was no significant impact on gross or net expenditures for Standard or New Entrant DCEs in PY2021, Standard DCEs significantly reduced acute care hospitalizations and skilled nursing facility days, and both Standard and New Entrant DCEs significantly reduced ED visits. Standard DCEs also reduced hospitalizations for ambulatory care sensitive conditions.

4

<sup>&</sup>lt;sup>44</sup> The transition from the GPDC Model to the ACO REACH Model was announced on February 24, 2022. The ACO REACH Model began on January 1, 2023.

<sup>&</sup>lt;sup>45</sup> https://www.cms.gov/priorities/innovation/innovation-models/gpdc-model



| Program/Model<br>Name   | Clinical Focus, Providers,<br>Setting, Patient Population   | Lessons Learned Related to Performance<br>Measurement   |
|---|---|---|
| Home Health Value-Based Purchasing (HHVBP) Model No Longer Active Years active: 2016-2021 | Clinical Focus: Home health care Providers: Medicarecertified Home Health Agencies (HHA) Setting: Home health setting Patient Population: Medicare beneficiaries requiring home health services | The seventh annual report <sup>46</sup> found HHVBP led to decreases in unplanned hospitalizations (-1.2%), skilled nursing facility use (-8.2%), and ED use followed by inpatient admissions (-1.5%), but an increase in outpatient ED visits (2.1%). In all model years (2016-2021), Home health agencies in participating states received higher TPS scores than agencies in non-HHVBP states and throughout the four payment years. The model also resulted in small improvements in patients' mobility, management of oral medicine, and self-care, and a greater proportion of patients were discharged to the community rather than institutional care. However, patient experience with professional care, communication, and discussion of care decreased during the model. The HHVBP model led to savings in Part A and Part B spending in all model years for a total of \$1.38 billion in savings. Reductions were attributed reduced spending on skilled nursing facility services, inpatient hospital stays, and home health spending but increased spending for outpatient ED and observational stays. |
| Independence at Home (IAH) Demonstration Ongoing Years Active: 2011-present               | Clinical Focus: Primary care, chronically ill  Providers: Primary care providers  Setting: Home-based  Patient Population:  Medicare beneficiaries with multiple chronic conditions             | An evaluation of performance years 1-7 <sup>47</sup> found the majority of practices reported they were already providing care that was largely consistent with the demonstration requirements and quality measures before participating in the program. Several practices also reported these guidelines became their standard of care for all patients. Nearly all 10 practices met the required threshold for claims-based measures (hospital admissions, ED visits, all-cause hospital readmissions), making them eligible for incentive payments, but most fell short of the threshold for site-reported measures (documenting patient preferences, follow-up within 48 hours, medication reconciliation within 48 hours). There was some improvement in practices documenting patient preferences between years 6 and 7, however performance remained low for the two measures requiring timely follow-up.  |

 $<sup>^{46}\</sup> https://www.cms.gov/priorities/innovation/innovation-models/home-health-value-based-purchasing-model$ 

<sup>&</sup>lt;sup>47</sup> https://www.cms.gov/priorities/innovation/data-and-reports/2023/iah-year7-eval-report



| Program/Model<br>Name   | Clinical Focus, Providers,<br>Setting, Patient Population   | Lessons Learned Related to Performance<br>Measurement  |
|---|---|--|
| Kidney Care<br>Choices (KCC)<br>Model<br>Ongoing<br>Years active:<br>2020-present           | Clinical Focus: ESRD  Providers: Accountable care/dialysis facilities, nephrologists, and other health care providers form ESRD-focused ACOs (Kidney Contracting Entities <sup>48</sup> [KCEs])  Setting: Dialysis facilities  Patient Population: Patients with ESRD | Model evaluations have not been completed yet.   |
| Making Care Primary (MCP) Model Accepting Applications Years active: Launching in July 2024 | Clinical Focus: Primary care Providers: PCPs Setting: Primary care practices Patient Population: All Medicare beneficiaries in participating regions  | MCP is a new, 10.5-year CMMI advanced primary care model that aims to reduce program expenditures and improve key measures of patient outcomes through more coordinated and integrated care. The model is currently accepting applications and does not yet have participants. Model evaluations have not been completed yet. Thus, there are no lessons learned related to performance measurement. |

<sup>&</sup>lt;sup>48</sup> Nephrology practices and their nephrologists and nephrology professionals who meet certain eligibility requirements can participate in the Kidney Care First (KCF) Option. KCEs can participate in any of the Comprehensive Kidney Care Contracting (CKCC) Options and are required to include nephrologists or nephrology practices and transplant providers; optional participants in KCEs include dialysis facilities and other suppliers and providers.



| Program/Model<br>Name  | Clinical Focus, Providers,<br>Setting, Patient Population  | Lessons Learned Related to Performance<br>Measurement  |
|--|--|--|
| Next Generation Accountable Care Organization (NGACO) No Longer Active Years active: 2016-2021 | Clinical Focus: Primary and specialty care Providers: Participating PCPs and specialists Setting: Primary and specialty care practices, hospitals, inpatient and outpatient settings Patient Population: Original Medicare FFS beneficiaries | An evaluation after the fifth performance year 49 found that the NGACO model was associated with \$1.05B in gross savings, or 1.5%, compared to FFs beneficiaries in the comparison group. In PY5, the NGACO model reduced gross spending by 3.1%. However, cumulative net Medicare spending increased by \$386.5M after taking into consideration shared savings and payments to the NGACOs. Additionally, some NGACOs reported increased resilience and improved response to the COVID-19 Public Health Emergency as a result of infrastructure, partnerships, and resources developed from participation in the NGACO model. The NGACOs also saw a reduction in hospital spending and utilization, SNF stays and days, and spending in institutional post-acute care (PAC) settings.  Larger spending and utilization reductions in PY5 are likely to have been a result of the selection effect of less successful NGACOs exiting the model. The NGACOs continuing in the model earned shared savings throughout the Model implementation, resulting in larger payouts and continuous improvement.  Annual wellness visits (AWVs) were measured under the evaluation; NGACO leadership reported using AWVs and IT infrastructure to identify and address gaps in care. |
| Oncology Care<br>Model (OCM)<br>No Longer Active<br>Years active:<br>2016-2022                 | Clinical Focus: Cancer care Providers: Oncology providers Setting: Outpatient Patient Population: Patients with cancer   | An evaluation after the ninth performance period found that OCM was associated with a reduction in TEP by 1.7%. However, net losses for Medicare exceeded \$500M. OCM increased the use of high-value supportive therapies. In terms of health equity, the report did not find evidence of improved care quality for Black, Hispanic, or dual-eligible beneficiaries across the measures included in the analysis. There was no effect on the timeliness of post-chemotherapy surgery, patient adherence to oral cancer regiments, or provision of higher-value palliative radiation.  |

<sup>49</sup> Fifth Evaluation Main Report (cms.gov)



| Program/Model   | Clinical Focus, Providers,   | Lessons Learned Related to Performance  |
|---|--|---|
| Name  | Setting, Patient Population  | Measurement   |
| Primary Care First (PCF) Model Options Ongoing Years active: 2021-present | Clinical Focus: Primary care Providers: PCPs Setting: Primary care practices Patient Population: Medicare patients with serious illness/chronic conditions | As of the first annual evaluation report, 50 most practices met benchmarks for diabetes control, high blood pressure control, and colorectal cancer screening. In addition, qualitative work showed that practices found advanced care plans to be burdensome and costly. Some practices noted that their previous success in reducing preventable hospital utilization could make it difficult to achieve further reductions. On average, PCF payments were higher than expected FFS payments. |

 $^{50} \ \underline{\text{https://innovation.cms.gov/data-and-reports/2022/pcf-first-eval-aag-rpt}}$ 



## Appendix D. Detailed Information on Current Performance Measures for Four Selected Medicare Payment Programs

Exhibit D1. Program Description, Technical Issues, and Gaps Related to Current Performance Measures

| Program/Model<br>Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance Measurement  | Technical Issues Related<br>to Performance<br>Measurement  | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable  |
|---|--|--|--|---|---|
| Hospital Value-Based Purchasing Program (Hospital VBP) Ongoing Years Active: 2013 – Present | Clinical Focus: Hospital care Providers: Acute care hospitals Setting: Inpatient services Patient Population: Medicare beneficiaries requiring inpatient hospital services | Utilization measure(s): N/A Quality measure(s): Acute Myocardial Infarction 30-Day Mortality Rate; Coronary Artery Bypass Graft Surgery 30-Day Mortality Rate; Chronic Obstructive Pulmonary Disease 30-Day Mortality Rate; Heart Failure 30-Day Mortality Rate; Pneumonia 30-Day Mortality Rate; Total Hip Arthroplasty/ Total Knee Arthroplasty/ Complication Rate  Spending measure(s): Medicare-severity diagnosis- related group (MS-DRG) payment amounts for Medicare FFS claims  Patient experience measure(s): N/A | How payment is adjusted for performance: Under the Inpatient Prospective Payment System (IPPS), payments are adjusted based on a total performance score that reflects relevant benchmarks, for each performance measure.  Requirements: The program withholds participants' payments by 2% percent; this amount is used to fund value-based incentive payments to participants based on performance.  Attribution: N/A  Volume: N/A | Measures used for implementation: All listed quality measures  Measures used for monitoring: Not specified  How achievement is measured: Participants earn 2 scores on each performance measure, one for achievement, based on how well they perform compared to all hospitals, and one for improvement, based on how much they improve their own performance compared to their | The hospital total performance score (TPS) is skewed and shows a large gap between topperforming hospitals and all others. The highest performing hospitals tend to maintain their position over time, which may discourage lowerperforming hospitals from program participation and improvement. <sup>51</sup> |

<sup>&</sup>lt;sup>51</sup> doi: 10.1111/1475-6773.13608



| Program/Model<br>Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population                               | Components Relevant to<br>Performance Measurement  | Technical Issues Related<br>to Performance<br>Measurement   | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable                               |
|---|---|--|---|---|--|
|   |   |  | Risk stratification or adjustment: Participants who treat a high percentage of low-income patients receive a disproportionate share hospital (DSH) adjustment, which is a percentage increase in Medicare payments to hospitals that serve a disproportionate amount of low-income patients. Further, participants who are approved teaching hospitals receive an indirect medical education (IME) adjustment. Lastly, for substantially costly/outlier cases, IPPS payment is increased.  Benchmarking: Historical national data | performance during baseline. The final score awarded for each measure is the higher of these 2 scores.  How improvement is measured: See how achievement is measured. |  |
| Medicare Advantage Star Ratings Program (MA Star Ratings Program) Ongoing | Clinical Focus: Total care Providers: Medicare Advantage Health Plan Contracts Setting: Broad | Utilization measure(s): N/A Quality measure(s): Special Needs Plan (SNP) Care Management; Statin Therapy for Patients with Cardiovascular Disease; Medication Reconciliation Post-Discharge; Improving | How payment is adjusted for performance: Star ratings (based on performance) are used to determine 1) whether a plan is eligible for a bonus payment; and 2) the percentage increase in   | Measures used for implementation: Quality and patient experience measures listed Measures used for monitoring: Quality and patient                                    | A report from McKinsey found that investments in patient-experience improvements have been low. 52 |

\_

 $<sup>^{52}\ \</sup>underline{\text{https://www.mckinsey.com/industries/healthcare/our-insights/assessing-the-medicare-advantage-stars-ratings}$ 



| Program/Model<br>Name           | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement  | Technical Issues Related<br>to Performance<br>Measurement  | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable |
|---------------------------------|---|--|--|---|--|
| Years Active:<br>2009 – Present | Patient Population: Medicare Advantage beneficiaries            | Bladder Control; Reviewing Appeals Decisions; Annual Flu Vaccine; Care Coordination; Plan makes Timely Decision about Appeals; Reducing the Risk of Falling; Call Center- Foreign Language Interpreter and TTY Availability; Colorectal Cancer Screening; Monitoring Physical Activity; Care for Older Adults – Pain Assessment; Care for Older Adults – Medication Review; Breast Cancer Screening; Diabetes Care – Blood Sugar Controlled; Diabetes Care – Eye Exam; Osteoporosis Management for Women who had a Fracture; Controlling Blood Pressure; Plan All- Cause Readmissions; Transitions of Care; Follow- up after Emergency Department Visit for People with Multiple High-Risk Chronic Conditions; Health Plan Quality Improvement Spending measure(s): Medicare FFS spending Patient experience measure(s): Getting Appointments and Care | payment benchmarks and rebate amounts.  Requirements: To be eligible for a performance-based bonus payment, health plan contracts must obtain a 4, 4.5, or 5 Star Rating.  Attribution: N/A  Volume: N/A; Plans without ratings due to low enrollment receive a small benchmark increase.  Risk stratification or adjustment: CMS includes a coding intensity adjustment that accounts for potential increases in the average risk score of MA beneficiaries. Adjustments to Star Ratings may also be made based on impacts due to public health emergencies (PHEs), such as COVID-19.  Benchmarking: Benchmarks are calculated separately for each county and are based on historic fee-for-service Medicare spending. Benchmarks are then adjusted by plan | experience measures listed and measures that were removed (not listed)  How achievement is measure: MA Health Plan Contracts receive a numeric measure score for each measure (up to 40 measures). Measures come from four sources: Healthcare Effectiveness Data and Information Set (HEDIS), Consumer Assessment of Healthcare Providers and Systems (CAHPS), Health Outcomes Survey (HOS), and CMS administrative data. Measures are weighted to reflect CMS priority in scoring MA plans. Process measures receive a weight of 1; patient experience measures receive a |  |



| Program/Model<br>Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement   | Technical Issues Related<br>to Performance<br>Measurement       | How Measurement<br>is Used to<br>Determine Success   | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable |
|-----------------------|---|---|---|--|--|
|                       |   | Quickly; Customer Service; Complaints about the Plan; Rating of Health Plan; Rating of Health Care Quality; Getting Needed Care; Members Choosing to Leave the Plan | quality (star rating). Benchmarks are capped at pre-ACA levels. | weight of 1.5; outcomes and intermediate outcomes a weight of 3; quality improvement measures a weight of 5. CMS calculates Star Ratings scores for each measure as well as a summary Star Rating score based on their performance in five domains: use of screenings, tests, and vaccines; management of chronic conditions; member experience with plans (CAHPS); member complaints and changes in plan's performance; and customer service/appeals. The numeric measure scores are converted to a Star Rating (from 1-5) based on one of two methods: clustering or relative distribution and significance testing. |  |



| Program/Model<br>Name   | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement   | Technical Issues Related<br>to Performance<br>Measurement   | How Measurement<br>is Used to<br>Determine Success   | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable                                  |
|---|---|---|---|--|---|
|   |   |   |   | cMS previously defined quality threshold values that a plan would need to achieve to receive four stars on certain measures. Because analysis determined that plans showed more improvement on measures without pre-determined thresholds, CMS eliminated pre-defined thresholds beginning in 2016.  How improvement is measured: Although not tied to payment, improvement is measured by comparing the health plan contract's current and prior year measure scores. |   |
| Merit-Based<br>Incentive<br>Payment System<br>(MIPS)<br>Ongoing | Clinical Focus: Total care Providers: Clinicians, practices     | Utilization measure(s): Hospital-Wide, 30-Day, All-Cause Unplanned Readmission (HWR) Rate for MIPS Eligible Groups; Clinician and Clinician Group | How payment is adjusted for performance: Payment adjustment applied to Medicare Part B claims based on performance. Performance is measured | Measures used for implementation: From the measures listed, participants select 6 measures or a complete specialty   | Few MIPS measures relate to aspects of access, patient experience, or physician interpersonal skills, |



| Program/Model<br>Name           | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement   | Technical Issues Related<br>to Performance<br>Measurement   | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable  |
|---------------------------------|---|---|---|---|---|
| Years Active:<br>2017 – Present | Setting: Broad Patient Population: Medicare FFS beneficiaries   | Risk-standardized Hospital Admission Rates for Patients with Multiple Chronic Conditions; Risk- Standardized Acute Unplanned Cardiovascular- Related Admission Rates for Patients with Heart Failure for MIPS  Quality measure(s): The 2023 MIPS Quality Measure List includes over 200 measures, 53 including Risk- Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) for MIPS  Spending measure(s): Total per capita cost; Medicare spending per beneficiary clinician; episode-based costs for 23 specific conditions  Patient experience measure(s): CAHPS for MIPS Survey | across 4 areas; quality, improvement activities, promoting interoperability, and cost. Participants receive a MIPS final score based on the four performance categories, which determines the payment adjustment.  Requirements: Participants must submit collected data for at least 6 quality measures and achieve at least 70% data completeness for each quality measure.  Attribution: N/A  Volume: Beginning in 2023, reporting a measure that does not meet the case minimum will result in 0 out of 10 points (3 points for small practices).  Risk stratification or adjustment: Expected costs for each episode use the CMS Hierarchical Condition Category (HCC) risk adjustment | measure set. CAHPS for MIPS Survey can count as 1 of the 6 minimum required quality measures.  Measures used for monitoring: Not specified.  How achievement is measured: Participants submit data for quality, improvement activities, and promoting interoperability; CMS calculates cost for participants. CMS automatically calculates and scores four administrative claims measures.  Measures are scored by comparing to measure-specific benchmarks. A maximum of 10 points can be earned for each measure. | which could contribute to or worsen health disparities. <sup>54</sup> |

 $^{53} \ \text{For the full 2023 MIPS Quality Measure List, see} \ \underline{\text{https://qpp-cm-prod-content.s3.amazonaws.com/uploads/2217/2023%20MIPS\%20Quality\%20Measures\%20List.xlsx}.$ 

<sup>&</sup>lt;sup>54</sup> https://www.annfammed.org/content/annalsfm/15/3/255.full.pdf



| Program/Model<br>Name  | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population  | Components Relevant to<br>Performance Measurement  | Technical Issues Related<br>to Performance<br>Measurement   | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable  |
|--|--|--|---|---|---|
|  |  |  | methodology; it adjusts for 12 age categorical variables and individual indicator variables for history of ESRD, long-term care status, comorbidities, and whether beneficiary qualifies for Medicare through disability or age.  Benchmarking: For each performance measure collection type, CMS establishes a benchmark based on historical data.             | Scores from 75-100 points will receive a payment adjustment ranging from 0-9% (e.g., MIPS score of 100 receives positive payment adjustment of 9%).  How improvement is measured: Participants are eligible to earn up to 10 additional percentage points based on improvement in performance from the previous year. |   |
| Medicare Shared<br>Savings<br>Program (MSSP)<br>Ongoing<br>Years Active:<br>2012-Present | Clinical Focus: Total care  Providers: Providers and suppliers (e.g., physicians, hospitals, and others involved in patient care) that create an Accountable Care Organization (ACO) | Utilization measure(s): Not specified  Quality measure(s): Depression remission at twelve months; falls: screening for future fall risk; hospital-wide, 30-day, all-cause unplanned readmission (HWR) rate for the MIPS Groups; preventive care and screening: influenza immunization; breast cancer screening; colorectal cancer screening; clinician and | How payment is adjusted for performance: ACOs are subject to an annual spending target (benchmark) and a series of quality thresholds. ACOs that spend less than the benchmark share the savings with CMS. There is a penalty for spending more than the threshold under the enhanced track. ACOs are subject to quality withholds from their shared savings if | Measures used for implementation: All quality, spending, and patient experience measures  Measures used for monitoring: CMS reports ACO-level setting-specific spending and utilization, including but not limited to categories of inpatient (e.g., short-   | In recent years, CMS has proposed changes to the program to promote equity, especially in rural and underserved areas. Access to ACOs appeared inequitable, based on data indicating that Black (or African American), Hispanic, Asian/Pacific Islander, and American |



| Program/Model<br>Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement  | Technical Issues Related<br>to Performance<br>Measurement  | How Measurement<br>is Used to<br>Determine Success   | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable  |
|-----------------------|---|--|--|--|---|
|                       | Setting: Broad Patient Population: Medicare FFS beneficiaries   | clinician group risk-adjusted hospital admission rates for patients with multiple chronic conditions; statin therapy for the prevention and treatment of cardiovascular disease; preventive care and screening: tobacco use: screening and cessation intervention; diabetes hemoglobin A1c (HbA1c) poor control (>9%); preventive care and screening: screening for depression and follow-up plan; controlling high blood pressure. MSSP ACOs are also given a quality score based on their performance on three quality measures related to care coordination/patient safety, preventive health, and control of diabetes, depression, and hypertension.  Spending measure(s): Medicare Part and Part B FFS claims  Patient experience measure(s): CAHPS for MIPS Clinician/Group Survey | they do not meet quality benchmarks.  Requirements: Participating ACOs must report quality data to CMS after the close of every performance year to be eligible to share in any earned shared savings and to avoid sharing losses at the maximum level.  Attribution: Voluntary: Beneficiaries confirm care relationships with a primary clinician who is an ACO professional participating in the ACO.  Prospective and retrospective claims-based: Based on receiving the plurality of primary care services from primary care physicians, nurse practitioners, physician assistants, clinical nurse specialists, or specialist physicians in the participating ACOs.  Volume: Not specified; as of 2020, average number of beneficiaries in an MSSP ACO is 20,700, with the | term acute care hospital) and outpatient (e.g., outpatient facility) expenditures as well as types of inpatient (e.g., hospital discharges) and outpatient (e.g., primary care services) utilization.  How achievement is measured: ACOs earn quality points on a sliding scale based on level of performance for each measure. The higher the level of performance, the higher the number of quality points earned. The total points earned are summed and divided by the total points available to determine the ACO's quality score. The percentage of shared savings varies based on the ACO's quality score. Additionally, ACOs | Indian/Alaska Native beneficiaries were less likely to be assigned to a Shared Savings Program ACO than their Non-Hispanic White counterparts. CMS proposed assigning more people who receive care from nurse practitioners, physician assistants, and clinical nurse specialists to ACOs in order to increase the number of people receiving high-quality, accountable care. CMS also proposed changes to the benchmark methodology to encourage ACOs caring for medically complex, high-cost beneficiaries to join the program. CMS previously established advance investment payments for ACOs in rural and underserved communities, made changes to the benchmark |



| Program/Model<br>Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement | Technical Issues Related<br>to Performance<br>Measurement  | How Measurement<br>is Used to<br>Determine Success  | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable  |
|-----------------------|---|---|--|---|---|
|                       |   |   | program including approximately 10.6 million attributed beneficiaries, or around 28% of Medicare fee-for-service beneficiaries.  Risk stratification or adjustment: When establishing the historical benchmark, CMS uses the hierarchical condition category (HCC) scores to adjust for changes in severity of the population assigned to the ACO between the first and third benchmark years and between the second and third benchmark years.  CMS risk-adjusts the county-level expenditures used in calculating the regional component of the national-regional blend growth rate used to trend the first and second benchmark years to the third benchmark years to the third benchmark year.  Under the two-sided risk model, shared losses are adjusted for the percentage of beneficiaries in counties affected by an extreme and uncontrollable | are assessed based on a combination of both reporting and quality performance requirements.  How improvement is measured: Beginning in Performance Year 2015, CMS introduced a Quality Improvement Reward that allows ACOs to earn up to four additional points in each quality domain if they show statistically significant improvement in their performance on quality measures from one year to the next. | methodology, increased the time for ACOs to transition to downside risk, and implemented a health equity adjustment that rewards excellent care delivered to underserved communities. |



| Program/Model<br>Name | Clinical Focus,<br>Providers,<br>Setting, Patient<br>Population | Components Relevant to<br>Performance Measurement | Technical Issues Related<br>to Performance<br>Measurement   | How Measurement<br>is Used to<br>Determine Success | Gaps Related to<br>Current Performance<br>Measures, as<br>applicable |
|-----------------------|---|---|---|--|--|
|                       |   |   | circumstance. Individual measures are risk-adjusted, as applicable. 55  |  |  |
|                       |   |   | Benchmarking: Yes, based on spending for beneficiaries who would have been assigned to the ACO in the baseline years and the region. When establishing the historical benchmark, CMS uses the HCC scores to adjust for changes in severity of the population assigned to the ACO. CMS risk-adjusts the county-level expenditures used in calculating the regional component of the national-regional blend growth rate. |  |  |

55

The HWR measure can assign each admission to multiple eligible clinician groups; thus, a two-step approach is used to account for clustering of patients in which five specialty cohort models are used to adjust for case mix differences among providers by risk adjusting for patients' comorbid conditions. The unplanned hospital admissions for patients with multiple chronic conditions measure uses a hierarchical statistical model that accounts for the clustering of patients within MIPS providers/ACOs and accommodates the varying patient sample sizes of different providers. The model adjusts for 47 demographic and clinical and two social risk factors.



Exhibit D2. Lessons Learned

| Program/Model<br>Name  | Clinical Focus, Providers, Setting,<br>Patient Population, and Attribution   | Lessons Learned Related to Performance Measurement   |
|--|--|--|
| Hospital Value-Based Purchasing Program (Hospital VBP) Ongoing Years Active: 2013 – Present            | Clinical Focus: Hospital care Providers: Acute care hospitals Setting: Inpatient services Patient Population: Medicare beneficiaries requiring inpatient hospital services | A review of studies that evaluated Hospital VBP between 2013-2019 found that Hospital VBP does not lead to meaningful improvements in quality of care or patient outcomes. According to this review, safety-net hospitals' outcomes may be negatively affected by participation in Hospital VBP. <sup>56</sup> More recent studies also did not observe associations between Hospital VBP program participation and improvements in health care quality or patient outcomes. <sup>57,58</sup> An analysis of data from California hospitals participating in the Hospital VBP program suggested that increasing the weight given to outcome measures may increase the quality of care delivered and reduce costs. <sup>59</sup>  |
| Medicare Advantage Star Ratings Program (MA Star Ratings Program) Ongoing Years Active: 2009 – Present | Clinical Focus: Total care Providers: Health plans Setting: Broad Patient Population: Medicare Advantage beneficiaries   | <ul> <li>A report from McKinsey<sup>60</sup> found that health plans can improve their Medicare Advantage (MA) Star Ratings scores in two areas:</li> <li>Outcome and process measures: as cut points for measures evolve, health plan contracts will have to continue to make improvements which could require long-term investments.</li> <li>Patient experience and access scores: health plan contracts will need to increase their focus on patient-experience and access measures as scores for these measures have seen less improvement than other domains.</li> <li>Further, improvements in digitization and analytics could help health plans engage beneficiaries and providers and decrease administrative burden.</li> <li>A report from Urban Institute<sup>61</sup> concluded that the star rating system and the quality bonus program (QBP) has many limitations:</li> <li>score inflation (generous bonuses and no downside risk/penalties for programs with low star ratings)</li> </ul> |

<sup>&</sup>lt;sup>56</sup> https://doi.org/10.1097/MLR.000000000001354

<sup>&</sup>lt;sup>57</sup> https://doi.org/10.2147/JMDH.S358733

<sup>&</sup>lt;sup>58</sup> https://link.springer.com/article/10.1186/s12913-019-4562-7

<sup>&</sup>lt;sup>59</sup> https://doi.org/10.1007/s40258-017-0357-3

https://www.mckinsey.com/industries/healthcare/our-insights/assessing-the-medicare-advantage-stars-ratings

<sup>61</sup> https://www.urban.org/sites/default/files/2023-06/The%20Medicare%20Advantage%20Quality%20Bonus%20Program.pdf



| Program/Model<br>Name  | Clinical Focus, Providers, Setting,<br>Patient Population, and Attribution  | Lessons Learned Related to Performance Measurement   |
|--|---|--|
|  |   | <ul> <li>limitations in underlying data sets, which lead to measures focused on the needs of younger and healthier beneficiaries</li> <li>performance is measured at the contract level and not plan level</li> <li>many beneficiaries do not use star ratings when selecting plans</li> </ul>   |
| Merit-Based Incentive Payment System (MIPS) Ongoing Years Active: 2017 – Present         | Clinical Focus: Total care Providers: Clinicians, practices Setting: Broad Patient Population: Medicare FFS beneficiaries   | Around half of clinicians only partially participated in the program (reporting data for only one or two of the three categories), including one quarter of clinicians who did not report quality measures. The average performance for each measure was very high, potentially due to selective participation and/or unambitious targets. Approximately 74% of clinicians who partially participated during the first year of MIPS received a positive payment adjustment. There are concerns that the design of MIPS may be too flexible to effectively incentivize clinicians to improve quality. <sup>62</sup> In addition, participation in MIPS was associated with increased after-hours documentation for physicians, suggesting that physicians may need resources to help reduce the reporting burden. <sup>63</sup>   |
| Medicare Shared<br>Savings<br>Program (MSSP)<br>Ongoing<br>Years Active:<br>2012-Present | Clinical Focus: Total care Providers: Providers and suppliers (e.g., physicians, hospitals, and others involved in patient care) that create an Accountable Care Organization (ACO) Setting: Broad Patient Population: Medicare FFS beneficiaries | Early performance results from CMS' Medicare Shared Savings Program Pathways to Success final rule suggest that ACOs with greater financial accountability (e.g., more accurate financial benchmarks, downside risk) are more likely to deliver better coordinated and efficient care for Medicare patients. As of 2022, MSSP had generated overall savings and high-quality performance results for six consecutive years. In the same year, ACOs had a higher average performance on quality measures they are required to report in order to share in savings, including statistically significant higher performance for quality measures related to diabetes and blood pressure control, breast cancer and colorectal cancer screening, tobacco screening and smoking cessation, and depression screening and follow-up, compared to other similarly sized clinician groups not in the program. ACOs that earned more shared savings tended to be low revenue, which may mainly be made up of physicians and may include a small hospital or serve rural areas. |

<sup>&</sup>lt;sup>62</sup> doi: 10.1377/hlthaff.2019.01648

<sup>63</sup> https://doi.org/10.1111/jep.13796



# Appendix E. Programs and Models Included in the CMIT Table, Detailed Tables, or Both

| Program/Model  | Program / Model<br>Type                   | Inclusion  | Appendix  |
|--|---|--|---|
| Medicare Shared Savings Program (MSSP)   | CMS Value-<br>Based<br>Payment<br>Program | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix D</li></ul> |
| Medicare Advantage (MA) Star Ratings<br>Program  | CMS Value-<br>Based<br>Payment<br>Program | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix D</li></ul> |
| Merit-Based Incentive Payment System (MIPS)<br>Program   | CMS Value-<br>Based<br>Payment<br>Program | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix D</li></ul> |
| Hospital Value-Based Purchasing (VBP)  | CMS Value-<br>Based<br>Payment<br>Program | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix D</li></ul> |
| Bundled Payment for Care Improvement<br>Advanced (BPCI-A) Model                                  | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| Accountable Care Organization (ACO) Realizing Equity, Access, and Community Health (REACH) Model | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| Independence at Home (IAH) Demonstration   | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| Kidney Care Choices (KCC) Model  | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| Home Health Value-Based Purchasing (HHVBP)   | CMS Value-<br>Based<br>Payment<br>Program | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| Oncology Care Model (OCM)  | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |



| Program/Model  | Program / Model<br>Type                   | Inclusion  | Appendix  |
|--|---|--|---|
| Primary Care First (PCF) Model   | CMMI Model                                | <ul><li> CMIT Table</li><li> Detailed Tables</li></ul> | <ul><li>Appendix B</li><li>Appendix C</li></ul> |
| End-Stage Renal Disease (ESRD) Quality Incentive Program (QIP)                                 | CMS Value-<br>Based<br>Payment<br>Program | CMIT Table   | Appendix B                                      |
| Long-Term Care Hospital (LTCH) Quality<br>Reporting Program (QRP)                              | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Skilled Nursing Facility (SNF) Quality Reporting Program (QRP)                                 | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Skilled Nursing Facility (SNF) Value-Based Purchasing (VBP)                                    | CMS Value-<br>Based<br>Payment<br>Program | CMIT Table   | Appendix B                                      |
| Inpatient Rehabilitation Facility (IRF) Quality Reporting Program (QRP)                        | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Inpatient Psychiatric Facility (IPF) Quality Reporting Program (QRP)                           | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Prospective Payment System (PPS)-Exempt<br>Cancer Hospital Quality Reporting (CHQR)<br>Program | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Hospital Outpatient Quality Reporting (OQR)<br>Program   | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Ambulatory Surgical Center (ASC) Quality<br>Reporting Program (QRP)                            | CMS Pay-For<br>Reporting<br>Program       | CMIT Table   | Appendix B                                      |
| Hospital Acquired Condition (HAC) Reduction Program  | CMS Value-<br>Based<br>Payment<br>Program | CMIT Table   | Appendix B                                      |



| Program/Model   | Program / Model<br>Type                   | Inclusion                           | Appendix   |
|---|---|-------------------------------------|------------|
| Hospital Readmission Reduction Program (HRRP)             | CMS Value-<br>Based<br>Payment<br>Program | CMIT Table                          | Appendix B |
| Hospice Quality Reporting Program (HQRP)                  | CMS Pay-For<br>Reporting<br>Program       | CMIT Table                          | Appendix B |
| Home Health Quality Reporting (QR)                        | CMS Pay-For<br>Reporting<br>Program       | CMIT Table                          | Appendix B |
| Making Care Primary (MCP) Model                           | CMMI Model                                | Detailed Tables                     | Appendix C |
| Enhancing Oncology Model (EOM)                            | CMMI Model                                | Detailed Tables                     | Appendix C |
| ESRD Treatment Choices (ETC) Model                        | CMMI Model                                | Detailed Tables                     | Appendix C |
| Expanded Home Health Value-Based Purchasing (HHVBP) Model | CMMI Model                                | Detailed Tables                     | Appendix C |
| Next Generation ACO (NGACO) Model                         | CMMI Model                                | Detailed Tables                     | Appendix C |
| Comprehensive ESRD Care (CEC) Model                       | CMMI Model                                | <ul> <li>Detailed Tables</li> </ul> | Appendix C |
| Comprehensive Primary Care Plus (CPC+)<br>Model           | CMMI Model                                | Detailed Tables                     | Appendix C |